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ABSTRACT
17b-Hydroxysteroid dehydrogenase type 1 (17b-HSD1) is a key enzyme in the biosynthesis of 17b-estra-
diol. Novel estrone-based compounds bearing various 15b-oxa-linked substituents and hydroxy, methoxy,
benzyloxy, and sulfamate groups in position C3 as potential 17b-HSD1 inhibitors have been synthesized.
In addition, in vitro inhibitory potentials measured in the presence of excess amount of NADPH or NADH
were investigated. We observed substantial inhibitory potentials for several derivatives (IC50< 1mM) and
increased binding affinities compared to unsubstituted core molecules. Binding and inhibition were found
to be cofactor-dependent for some of the compounds and we propose structural explanations for this
phenomenon. Our results may contribute to the development of new 17b-HSD1 inhibitors, potential drug
candidates for antiestrogen therapy of hormone-dependent gynecological cancers.
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Introduction
The 17b-hydroxysteroid dehydrogenase type 1 (17b-HSD1, EC
1.1.1.62) catalyzes the conversion of estrone (1) to highly active
estrogen 17b-estradiol (2) (Scheme 1). Human 17b-HSD1 is
expressed in tissues of female reproductive organs (such as pla-
centa, ovarian follicles, mammary gland and uterus)1. The expres-
sion of 17b-HSD1 was shown to be elevated and to have
prognostic significance in gynecological malignancies, e.g. in hor-
mone-dependent breast cancer2–4. The enzyme is involved in pro-
gression of these diseases due to the increase of local 17b-
estradiol (2) levels. Inhibition of the enzyme is able to control
estrogen actions at the pre-receptor level; therefore, a suppression
of the 17b-HSD1 activity has a significant therapeutic potential5.
Numerous 17b-HSD1 inhibitors based on either steroidal or non-
steroidal structures have been developed, but none of them have
been introduced to the medical practice, so far6–11.
Extensive earlier studies indicated that attachment of C15 sub-
stituents on the estrone scaffold might be a successful way for the
synthesis of inhibitors against 17b-HSD112,13. In addition to improv-
ing binding affinity to 17b-HSD1, appropriate side chains may con-
fer selectivity towards 17b-HSD type 27,10,14. 17b-HSD type 2
catalyzes inactivation of 17b-estradiol (2) to estrone (1) and is con-
sidered to be an important enzyme for the control of proliferation
of breast cancer cells15. C15 substituents may also suppress inher-
ent estrogenicity of the estrone core9,10,12,16. These features of C15
derivatives make this substitution strategy particularly attractive for
the development of estrone-based 17b-HSD1 inhibitors.
It was shown that neither the presence of the phenolic
hydroxyl group nor the hydrogen bonding of the C3 function is
essential to the effective 17b-HSD1 binding of estrone deriva-
tives17. This tolerance provides further options for the modulation
of enzyme inhibition and other biological effects of the candidate
compounds. Accordingly, several 3-methoxy analogues were
tested as 17b-HSD1 inhibitors12,13 presumably that they exert
reduced estrogenicity compared to estrone possessing phenolic
hydroxy group18. Estrone 3-sulfamate analogues in this series tend
to show moderate 17b-HSD1 inhibition13. However, the sulfamate
moiety may lead to an inhibitory effect against steroid sulfatase
(STS), another enzyme playing a central role in 17b-estradiol bio-
synthesis. Such a dual inhibitory effect was recently proposed to
be beneficial as it should result in a stronger suppression of estro-
gen biosynthesis compared to selective inhibition of 17b-HSD119.
Steroidal sulfamates may be delivered to the tumour by the car-
bonic anhydrase II, and evolve targeted actions20.
In this paper, we report the synthesis and chemical character-
ization of new substituted 15b-alkoxy estrone derivatives. We also
aimed to investigation 17b-HSD1 inhibitory potentials of these
compounds, including comparison of their inhibitor potentials
measured in the presence of NADPH or NADH.
Experimental
General
Melting points (mp) were determined on a Kofler block and are
uncorrected. Specific rotations were measured in CHCl3, or MeOH
(c 1) at 25 C with a POLAMAT-A (Zeiss-Jena) polarimeter and are
given in units of 101deg cm2 g1. Elementary analysis data were
determined with a PerkinElmer CHN analyzer model 2400.
Reactions were monitored by TLC on Kieselgel-G (Merck Si 254 F)
layers (0.25mm thick); solvent systems (ss): (A) (ethyl acetate/
CH2Cl2 (1:1 v/v), (B) acetone/toluene/hexane (30:35:35 v/v), (C)
ethyl acetate/CH2Cl2 (5:95 v/v), (D) ethyl acetate. The spots were
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detected by spraying with 5% phosphomolybdic acid in 50%
aqueous H3PO4. The Rf values were determined for the spots
observed by illumination at 254 and 365 nm. Flash chromatog-
raphy: silica gel 60, 40–63 lm. All solvents were distilled immedi-
ately prior to use. NMR spectra were recorded on a Bruker DRX
500 instrument at 500 (1H NMR) or 125MHz (13C NMR). Chemical
shifts are reported in ppm (d scale), and coupling constants (J) in
Hz. For the determination of multiplicities, the J-MOD pulse
sequence was used.
Materials for enzyme experiments
Radiolabelled steroids [6,7-3H(N)]estrone (S. A. ¼ 52 Ci/mmol), was
obtained from American Radiolabeled Chemicals (St. Louis, MO,
USA). Non-radioactive estrone, 3-methyl-O-estrone, 3-benzyl-O-
estrone and estrone-3-sulfamate (EMATE) standards and other
chemicals and solvents of analytical grade purity were purchased
from Sigma (St. Louis, MO, USA), from Fluka (Buchs, Switzerland)
or Merck (Darmstadt, Germany).
Human placenta microsomal fraction and cytosol were pro-
duced and applied with the permission of the Human
Investigation Review Board of the University of Szeged.
General procedure for the synthesis of 3-methoxy-, and 3-
benzyloxy-15b-alkoxyestra-1,3,5(10)-trien-17-ones (8–12)
A solution of 623 or 712 (2mmol) in CH2Cl2 (10ml) and ethane-1,2-
diol, propane-1,3-diol or butane-1,4-diol (15ml), containing 5%
aqueous sodium hydroxide (1ml) was stirred at room temperature
for 6 h. The reaction mixture, after the addition of CH2Cl2 (50ml),
was diluted with water (100ml). The organic phase was separated,
washed with water, dried over Na2SO4, and evaporated in vacuo.
The residual product was purified by flash chromatography using
ethyl acetate/CH2Cl2 in different proportions.
3-Methoxy-15b-(2’-hydroxy)ethoxy-estra-1,3,5(10)-trien-17-one (8)
Compound 6 (565mg, 2mmol) and ethane-1,2-diol (15ml) were
used for the synthesis as described in general procedure. The
crude product was chromatographed on silica gel with dichloro-
methane/hexane (1:1 v/v) to yield pure 8 (580mg, 84%). Mp:
139–140 C; Rf¼ 0.55 (ss B); [a]D20 þ 54 (c 1 in CHCl3). Found: C,
73.45; H, 7.98. C21H28O4 (344.45) requires: C,73.23; H, 8.19%.
1H
NMR (d, ppm, CDCl3): 1.16 (s, 3H, 18-H3), 2.92 (m, 2H, 6-H2), 3.42
and 3.64 (2xm, 2x1H, linker H2), 3.72 (m, 2H, linker OCH2), 3.77 (s,
3H, 3-OCH3), 4.22 (t, 1 H, J¼ 5.3 Hz, 15-H), 6.64 (d, 1H, J¼ 2.2 Hz, 4-
H), 6.71 (dd, 1H, J¼ 8.6 Hz, J¼ 2.2 Hz, 2-H), 7.19 (d, 1H, J¼ 8.6 Hz,
1-H).13C NMR (d, ppm, CDCl3):17.5 (C-18), 25.6, 26.2, 29.4, 32.5,
34.8, 43.1, 44.0, 47.2 (C-13), 54.4, 55.1 (3-OCH3), 61.9 (CH2-OH),
70.7 (linker CH2), 75.1 (C-15), 111.4 (C-2), 113.8 (C-4), 126.0 (C-1),
132.0 (C-10), 137.6 (C-5), 157.5 (C-3), 219.4 (C-17).
3-Methoxy-15b-(3’-hydroxy)propoxy-estra-1,3,5(10)-trien-17-one (9)
Compound 6 (565mg, 2mmol) and propane-1,3-diol (15ml) were
used for the synthesis as described in general procedure. The
crude product was chromatographed on silica gel with ethyl acet-
ate/CH2Cl2 (1:99 v/v) to yield pure 9 (575mg, 80%). Mp: 83–84 C;
Rf¼ 0.50 (ss B); [a]D20 þ 48 (c 1 in CHCl3). Found: C, 73.92; H,
8.26%. C22H30O4 requires: C, 73.71; H, 8.44%.
1H NMR (d, ppm,
CDCl3): 1.15 (s, 3H, 18-H3), 2.94 (m, 2H, 6-H2), 3.42 (m, 1H) and
3.74 (m, 3H): 2xlinker H2, 3.77 (s, 3H, 3-OCH3), 4.17 (t, 1 H,
J¼ 5.3 Hz, 15-H), 6.64 (d, 1H, J¼ 2.2 Hz, 4-H), 6.71 (dd, 1H,
J¼ 8.6 Hz, J¼ 2.2 Hz, 2-H), 7.19 (d, 1H, J¼ 8.6 Hz, 1-H).13C NMR (d,
ppm, CDCl3):17.4 (C-18), 25.7, 26.2, 29.4, 32.3, 32.6, 34.9, 42.8, 44.1,
47.2 (C-13), 54.2, 55.1 (3-OCH3), 61.5 (CH2-OH), 68.3 (linker CH2),
75.1 (C-15), 111.4 (C-2), 113.8 (C-4), 126.1 (C-1), 131.9 (C-10), 137.7
(C-5), 157.5 (C-3), 219.5 (C-17).
3-Benzyloxy-15b-(2’-hydroxy)ethoxy-estra-1,3,5(10)-trien-17-
one (10)
Compound 7 (717mg, 2mmol) and ethane-1,2-diol (15ml) were
used for the synthesis as described in general procedure. The
crude product was chromatographed on silica gel with ethyl acet-
ate/CH2Cl2 (30:70 v/v) to yield pure 10 (690mg, 82%). Mp:
102–104 C; Rf¼ 0.45 (ss B); [a]D20 þ 73 (c 1 in CHCl3). Found: C,
76.95; 7.84. C27H32O4 (420.54) requires: C, 77.11; H, 7.67%.
1H NMR
(d, ppm, CDCl3): 1.17 (s, 3H, 18-H3), 2.91 (m, 2H, 6-H2), 3.42 and
3.65 (2xm, 2x1H, linker H2), 3.73 (m, 2H, linker OCH2), 4.23 (t, 1 H,
J¼ 5.7 Hz, 15-H), 5.04 (s, 2H, Bn-H2), 6.74 (d, 1H, J¼ 2.2 Hz, 4-H),
6.79 (dd, 1H, J¼ 8.6 Hz, J¼ 2.2 Hz, 2-H), 7.19 (d, 1H, J¼ 8.6 Hz, 1-H),
7.32 (t, 1H, J¼ 7.3 Hz, 4-H of Bn), 7.39 (t, 2H, J¼ 7.3 Hz, 3-H and 5-
H of Bn), 7.45 (d, 2H, J¼ 7.3 Hz, 2-H and 6-H of Bn).13C NMR (d,
ppm, CDCl3): 17.6 (C-18), 25.7, 26.2, 29.5, 32.7, 34.9, 43.1, 44.2, 47.2
(C-13), 54.5, 62.0 (CH2-OH), 70.0 (linker CH2), 70.8 (Bn-CH2), 75.2
(C-15), 112.4 (C-2), 114.9 (C-4), 126.1 (C-1), 127.4 (2 C: C-2 and C-6
of Bn), 127.8 (C-4 of Bn), 128.5 (2 C: C-3 and C-5 of Bn), 132.4 (C-
10), 137.2 (C-1 of Bn), 137.7 (C-5), 156.9 (C-3), 219.1 (C-17).
3-Benzyloxy-15b-(3’-hydroxy)propoxy-estra-1,3,5(10)-trien-17-
one (11)
Compound 7 (717mg, 2mmol) and propane-1,3-diol (15ml) were
used for the synthesis as described in general procedure. The
crude product was chromatographed on silica gel with ethyl acet-
ate/CH2Cl2 (30:70 v/v) to yield pure 11 (742mg, 78%). Mp:
144–146 C; Rf¼ 0.35 (ss B); [a]D25 þ 88 (c 1 in CHCl3). Found: C,
77.54; H, 8.02. C28H34O4 (434.57) requires: C, 77.39; H, 7.89%.
1H
NMR (d, ppm, CDCl3): 1.15 (s, 3H, 18-H3), 2.94 (m, 2H, 6-H2), 3.36 (t,
2H, J¼ 6.0 Hz, linker H2), 3.72 (m, 2H, linker H2), 4.17 (t, 1 H,
J¼ 6.5 Hz, 15-H), 5.03 (s, 2H, H2 of Bn), 6.73 (d, 1H, J¼ 3.0 Hz, 4-H),
6.78 (dd, 1H, J¼ 10.5 Hz, J¼ 3.0 Hz, 2-H), 7.18 (d, 1H, J¼ 10.5Hz, 1-
H), 7.37 (m, 5H, 5x CH of Bn). 13C NMR (d, ppm, CDCl3): 18.0 (C-
18), 26.2, 26.6, 30.0, 32.8, 33.2, 35.4, 43.3 (linker CH2), 44.7, 47.7 (C-
13), 54.8, 62.1 (CH2-OH), 68.9 (OCH2), 70.4 (Bn-CH2), 75.7 (C-15),
112.8 (C-2), 115.4 (C-4), 126.6 (C-1), 127.9 (C-2 and -6 of Bn), 128.3
(C-4 of Bn), 129.0 (C-3and C-5 of Bn), 132.8 (C-10), 138.0 (C-1 of
Bn), 138.3 (C-5), 157.4 (C-3), 219.7 (C-17)
3-Benzyloxy-15b-(4’-hydroxy)butoxy-estra-1,3,5(10)-trien-17-
one (12)
Compound 7 (717mg, 2mmol) and butane-1,4-diol (15ml) were
used for the synthesis as described in general procedure. The
crude product was chromatographed on silica gel with ethyl
Scheme 1. Transformation of estrone to 17b-estradiol catalyzed by 17b-HSD1.
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acetate/CH2Cl2 (1:1 v/v) to yield pure 12 (720mg, 80%). Mp:
131–130 C; Rf¼ 0.30 (ss B); [a]D25 þ 58 (c 1 in CHCl3). Found: C,
77.48; H, 9.15. C29H36O4 (448.59) requires: C, 77.64; H, 8.09%.
1H
NMR (d, ppm, CDCl3): 1.16 (s, 3H, 18-H3), 3.34 (m, 2H, linker H2,
3.64 (m, 2H, O-CH2), 4.14 (t, 1 H, J¼ 6.5 Hz, 15-H), 5.03 (s, 2H, H2 of
Bn), 6.73 (d, 1H, J¼ 3.0 Hz, 4-H), 6.78 (dd, 1H, J¼ 10.5Hz, 2-H),
J¼ 3.0 Hz, 2H), 7.18 (d, 1H, J¼ 10.5Hz, 1-H), 7.36 (m, 5H, 5x CH of
Bn). 13C NMR (d, ppm, CDCl3): 18.0 (C-18), 26.2, 26.8, 27.0, 30.0,
33.2, 35.3, 41.9, 43.7 (linker CH2), 44.7, 47.7 (C-13), 55.0, 63.0
(CH2OH), 69.9 (OCH2), 70.5 (CH2 of Bn), 75.2 (C-15), 112.8 (C-2),
115.4 (C-4), 126.6 (C-1), 126.6 (C-2 and C-6 of Bn), 127.8 (C-4 of
Bn), 128.3 (C-3 and C-5 of Bn), 132.9 (C-10), 138.0 (C-1 of Bn),
138.3 (C-5), 157.3 (C-3), 220.2 (C-17).
3-Methoxy-15b-(carboxyl)methoxy-estra-1,3,5(10)-trien-17-one (13)
Compound 8 was dissolved in acetone (15ml). Jones reagent
(1ml) was added while cooling with ice. The mixture was diluted
with ice-water, and the precipitate was filtered off, washed with
water and dried. The crude product was dissolved in CH2Cl2 and
was chromatographed on silica gel with ethyl acetate/CH2Cl2
(25:75 v/v), yielding pure 13 (285mg, 39%). Mp: 142–144 C;
Rf¼ 0.32 (ss B); [a]D25 þ 42 (c 1 CHCl3). Found C, 70.54; H, 7.43.
C21H26O5 (358.43) requires: C, 70.73; H, 7.31%.
1H NMR (d, ppm,
DMSO-d6): 1.08 (s, 3H, 18-H3), 2.82 (m, 2H, 6-H2), 3.69 (s, 3H, 3-
OCH3), 4.05 (m, 2H, O-CH2), 4.29 (t, 1 H, J¼ 5.5 Hz, 15-H), 6.63 (s,
1H, 4-H), 6.68 (dd, 1H, J¼ 8.5 Hz, J¼ 2.0 Hz, 2-H), 7.17 (d, 1H,
J¼ 8.5 Hz, 1-H), 12.60 (brs, 1H, OH). 13C NMR (d, ppm, DMSO-d6):
17.2 (C-18), 25.3, 25.4, 29.1, 32.4, 34.7, 42.5 (C-13), 43.7, 46.5, 53.2,
54.8 (3-OCH3), 65.8 (O-CH2), 74.9 (C-15), 111.4 (C-2), 113.5 (C-4),
126.0 (C-1), 131.8 (C-10), 137.4 (C-5), 157.1 (C-3), 171.9 (COOH),
218.8 (C-17).
3-Methoxy-15b-(2’-carboxyl)ethoxy-estra-1,3,5(10)-trien-17-
one (14)
Compound 9 was dissolved in acetone (15ml). Jones reagent
(1ml) was added during cooling with ice. The mixture was diluted
with ice-water, and extracted with CH2Cl2. The organic phase was
evaporated to dryness and subjected to chromatographic separ-
ation on silica gel in ethyl acetate/CH2Cl2 (1:1 v/v), yielding pure
14 (346mg, 46%). Mp: 150–152 C; Rf¼ 0.30 (ss B); [a]D25 þ 46 (c
1 in CHCl3). Found: C, 71.15; H, 7.32. C22H28O5 (372.46) requires: C,
70.94; H, 7.58%. 1H NMR (d, ppm, CDCl3): 1.14 (s, 3H, 18-H3), 2.91
(m, 2H, 6-H2), 3.59 (m, 1H, 14-H), 3.80 (s, 4H, 2x linker H2), 4.21 (t,
1 H, J¼ 6.5 Hz, 15-H), 6.66 (s, 1H, 4-H), 6.73 (dd, 1H, J¼ 10.5 Hz,
J¼ 3.0 Hz, 2-H), 7.21 (d, 1H, J¼ 10.5 Hz, 1-H). 13C NMR (d, ppm,
CDCl3): 18.0 (C-18), 26.2, 26.6, 29.9, 33.1, 35.2, 35.5, 43.3, 44.6
(linker CH2), 47.7 (C-13), 54.9, 55.6 (3-OCH3), 65.0 (linker CH2), 75.4
(C-15), 111.7 (C-2), 114.5 (C-4), 126.6 (C-1), 132.6 (C-10), 138.3 (C-
5), 158.0 (C-3), 177.2 (COOH), 220.1 (C-17).
3-Benzyloxy-15b-(2’-carboxyl)ethoxy-estra-1,3,5(10)-trien-17-
one (15)
Compound 11 (435mg, 1mmol) was dissolved in acetone (10ml)
and Jones reagent (1ml) was added while cooling with ice. The
mixture was diluted with ice-water, the precipitate separating out
was filtered, dried and recrystallized from CH2Cl2/hexane, yielding
15 (342mg, 76%). Mp: 184–186 C; Rf¼ 0.30 (ss B); [a]D20 þ 98 (c
1 in CHCl3). (Found: C, 74.86; H, 7.35. C28H32O5 (448.55) requires:
C, 74.79; H, 7.19%). 1H NMR (d, ppm, CDCl3): 1.15 (s, 3H, 18-H3),
2.93 (m, 2H, 6-H2), 3.60 (m, 1H, O-CH2), 3.81 (m, 1H, O-CH2), 4.21
(t, 1H, J¼ 6.5 Hz, 15-H), 5.06 (s, 2H, Bn-H2), 6.75 (s, 1H, 4-H), 6.80
(dd, 1H, J¼ 10.5 Hz, J¼ 3.0 Hz, 2-H), 7.21 (d, 1H, J¼ 10.5 Hz, 1-H),
7.40 (m, -5H, 5x CH of Bn). 13C NMR (d, ppm, CDCl3): 17.8 (C-18),
26.2, 26.6, 29.9, 33.2, 35.2, 35.5, 43.3 (linker CH2), 44.6, 47.7 (C-13),
54.9, 65.0 (O-CH2), 70.4 (Bn-CH2), 75.4 (C-15), 112.6 (C-2), 115.5 (C-
4), 126.6 (C-1), 127.9 (C-2 and C-6 of Bn), 128.3 (C-4 of Bn), 129.0
(C-3 and C-5 of Bn), 132.9 (C-10), 138.0 (C-1 of Bn), 138.4 (C-5),
157.3 (C-3), 177.3 (COOH), 220.1 (C-17).
3-Hydroxy-15b-(2’-carboxyl)ethoxy-estra-1,3,5(10)-trien-17-one (16)
Compound 15 (448mg, 1mmol) was dissolved in ethyl acetate
(30ml) and the solution containing Pd/C (300mg, 10%) was
hydrogenated under 5 bar for 6 h at room temperature. The solu-
tion was filtered off, the residue was crystallized from methanol to
yield 16 (320mg, 89%). Mp: 200–202 C; Rf¼ 0.2 (ss B); [a]D25 þ
29 (c 1 in CHCl3). Found C, 70.18; H, 7.45. C21H26O5 requires: C,
70.37; H, 7.31%. 1H NMR (d, ppm, DMSO): 0.78 (s, 3H, 18-H3), 2.52
(m, 2H, 6-H2), 3.18 (m, 6H, 2x linker H2), 3.90 (t, 1 H, J¼ 6.5 Hz, 15-
H), 6.24 (d, 1H, J¼ 2.5 Hz, 4-H), 6.29 (dd, 1H, J¼ 10.5 Hz, J¼ 2.5 Hz,
2-H), 6.81 (d, 1H, J¼ 10.5 Hz, 1-H). 13C NMR (d, ppm, DMSO-d6):
17.6 (C-18), 25.8, 26.0, 29.3, 32.7, 35.1, 35.4, 43.1 (linker CH2), 43.9,
46.9 (C-13), 53.6, 65.1 (linker CH2), 74.6 (C-15), 113.1 (C-2), 115.4
(C-4), 126.2 (C-1), 130.6 (C-10), 137.6 (C-5), 155.4 (C-3), 173.1
(COOH), 219.3 (C-17).
3-Benzyloxy-15b-(3’-carboxyl)propoxy-estra-1,3,5(10)-trien-17-
one (17)
Compound 12 (448mg, 1mmol) was dissolved in acetone (10ml)
and Jones reagent (1ml) was added while cooling with ice. The
mixture was diluted with ice-water, the precipitate separating out
was filtered, dried, and crystallized from acetone/hexane to yield
17 (390mg, 84%). Mp: 138–140 C; Rf¼ 0.25 (ss B); [a]D25 þ 57 (c
1 in CHCl3). Found: C, 75.22; H, 7.67. C29H34O5 (462.58) requires: C,
70.30; H, 7.41%. 1H NMR (d, ppm, CDCl3): 1.14 (s, 3H, 18-H3), 3.29
(m, 1H, O-CH2), 3.56 (m, 1H, O-CH2), 4.12 (t, 1 H, J¼ 6.5 Hz, 15-H),
5.02 (s, 2H, Bn-H2), 6.73 (d, 1H, J¼ 3.0 Hz, 4-H), 6.77 (dd, 1H,
J¼ 10.5 Hz, J¼ 3.0 Hz, 2-H), 7.18 (d, 1H, J¼ 10.5 Hz, 1-H), 7.36 (m,
5H, 5x CH of Bn). 13C NMR (d, ppm, CDCl3): 18.0 (C-18), 25.5, 26.2,
26.8, 29.9, 31.3, 33.1, 35.3, 43.5 (linker CH2), 44.7, 47.7 (C-13), 55.0,
68.6 (O-CH2), 70.4 (Bn-CH2), 75.3 (C-15), 112.8 (C-2), 115.4 (C-4),
126.6 (C-1), 127.8 (C-2 and C-6 of Bn), 128.3 (C-4 of Bn), 129.0 (C-3
and C-5 of Bn), 132.9 (C-10), 137.7 (C-1 of Bn), 138.3 (C-5), 157.3
(C-3), 179.5 (COOH), 220.2 (C-17).
3-Methoxy-15b-(2’-cyano)ethoxy-estra-1,3,5(10)-trien-17-one (18)
Compound 6 (282mg, 1mmol) was dissolved in CH2Cl2 (10ml)
and 3-hydroxypropionylnitrile (10ml), containing 5% aqueous
NaOH (1ml), was stirred at room temperature for 8 h. CH2Cl2
(50ml) was added to the reaction mixture and then it was diluted
with water (100ml). The organic phase was separated, washed
with water, dried over Na2SO4, and evaporated in vacuo. The
residual product was purified by flash chromatography using
CH2Cl2 to yield 18 (305mg, 86%). Mp: 197–200 C; Rf¼ 0.50 (ss B);
[a]D
25 þ 63 (c 1 in CHCl3). Found C, 74.92; H, 7.55. C22H27NO3
(353.45) requires C, 74.76; H, 7.70%. 1H NMR (d, ppm, CDCl3): 1.17
(s, 3H, 18-H3), 2.60 (s 2H, linker H2), 3.00 (m, 2H, 6-H2), 3.65 (s, 3H,
3OCH3), 3.77 (s, 2’H, linker H2), 16-H2), 4.23 (t, 1 H, J¼ 6.4 Hz, 15-H),
6.65 (s, 1H, 4-H), 6.71 (d, 1H, J¼ 10.5 Hz, 2-H), 7.19 (d, 1H,
J¼ 10.5 Hz, 1-H). 13C NMR (d, ppm, CDCl3): 18.2 (C-18), 20.0, 26.4,
27.1, 30.1, 33.4, 35.4, 43.5, 44.9 (linker CH2), 47.9 (C-13), 55.1 (3-
OCH3), 55.9, 65.0 (O-CH2), 72.2 (C-15), 112.2 (C-2), 114.6 (C-4),
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118.3 (CN), 126.8 (C-1), 132.7 (C-10), 138.5 (C-5), 158.3 (C-3), 219.2
(C-17).
3-Benzyloxy-15b-(2’-cyano)ethoxy-estra-1,3,5(10)-trien-17-one (19)
Compound 7 (358mg, 1mmol) dissolved in CH2Cl2 (10ml) and 3-
hydroxypropionytrile (10ml), containing 5% aqueous NaOH (1ml),
was stirred at room temperature for 8 h. After adding CH2Cl2
(50ml) to the reaction mixture, the organic phase was separated,
washed with water, dried over Na2SO4, and evaporated in vacuo.
The residual product was purified by flash chromatography using
ethyl acetate/CH2Cl2 (2.5/97.5 v/v) to yield 19 (346mg, 80%). Mp:
183–185 C; Rf¼ 0.45 (ss B); [a]D25 þ 54 (c 1 in CHCl3). Found C,
78.52; H, 7.42. C28H31NO3 (429.55) requires: C, 78.29; H, 7.27%.
1H
NMR (d, ppm, CDCl3): 1.20 (s, 3H, 18-H3), 3.54 (m, 1H, O-CH2), 3.78
(m, 1H, O-CH2), 4.27 (t, 1 H, J¼ 6.5 Hz, 15-H), 5.07 (s, 2H, Bn-H2),
6.78 (s, 1H, 4-H), 6.81 (d, 1H, J¼ 11.0Hz, 2-H), 7.22 (d, 1H,
J¼ 11.0Hz, 1-H), 7.41 (m, 5H, 5x CH of Bn). 13C NMR (d, ppm,
CDCl3): 18.0 (C-18), 19.8, 26.2, 26.8, 29.9, 33.2, 35.2, 43.3 (CN), 44.7,
47.7 (C-13), 54.9, 64.8 (O-CH2), 70.4 (Bn-CH2), 76.0 (C-15), 112.8 (C-
2), 115.4 (C-4), 118.1 (CN), 126.6 (C-1), 127.9 (C-2 and C-6-of Bn),
128.3 (C-4-of Bn), 129.0 (C-3 and C-5 of Bn), 132.7 (C-10), 137.7 (C-
1 of Bn), 138.4 (C-5), 157.4 (C-3), 219.1 (C-17).
3-Hydroxy-15b-(2’-cyano)ethoxy-estra-1,3,5(10)-trien-17-one (20)
Compound 19 (430mg, 1mmol) was dissolved in ethyl acetate
(30ml) and the solution containing Pd/C (300mg, 10%) was
hydrogenated under 5 bar pressure for 6 h, at room temperature.
The reaction mixture was filtered off, evaporated in vacuo and
crystallized from CH2Cl2/hexane to yield 20 (286mg, 84%). Mp:
221–223 C; Rf¼ 0.25 (ss A); [a]D25 þ 37 (c 1 in MeOH). Found C,
74.62; H, 7.35. C21H25O3N (339.43) requires: C, 74.31; H, 7.42%.
1H
NMR (d, ppm, DMSO-d6): 1.07 (s, 3H, 18-H3), 2.76 (m, 2H, 6-H2),
3.33 (s, 3H, CN-H2), 15-H), 3.70 (m, 1H, O-CH2), 4.04 (m, 1H, O-CH2),
4.21 (t, 1 H, J¼ 6.5 Hz, 15-H), 6.47 (d, 1H, J¼ 3.0 Hz, 4-H), 6.53 (dd,
1H, J¼ 10.5 Hz, J¼ 3.0 Hz, 2-H), 7.05 (d, 1H, J¼ 10.5 Hz, 1-H), 9.00
(brs, 1H, 3-OH). 13C NMR (d, ppm, DMSO-d6): 17.2 (C-18), 18.5,
25.4, 25.7, 28.9, 32.3, 34.7, 42.7 (linker CH2), 43.5, 46.5 (C-13), 53.1,
63.7 (O-CH2), 74.5 (C-15), 112.7 (C-2), 115.0 (C-4), 119.2 (CN), 125.9
(C-1), 130.1 (C-10), 137.2 (C-5), 155.0 (C-3), 218.6 (C-17).
3-Sulfamoyloxy-15b-(2’-cyano)ethoxy-estra-1,3,5(10)-trien-17-
one (21)
Compound 20 (340mg, 1mmol) was dissolved in dimethylforma-
mide (20ml), and 575mg (5mmol) sulfamoylchloride was added
dropwise during cooling with ice. The reaction mixture was
allowed to stand 6 h and then poured onto ice (300 g). The pre-
cipitate was filtered off and dried. The product was crystallized
from ethyl acetate to yield 21 (360mg, 86%). Mp: 78–80 C;
Rf¼ 0.30 (ss A); [a]D25 þ 52 (c 1 in CHCl3). Found: C, 60 55; H, 6.42.
C21H26N2O5S (418.51) requires: C, 60.27; H, 6.26%.
1H NMR (d,
ppm, CDCl3): 1.10 (s, 3H, 18-H3), 3.45 (m, 1H, O-CH2), 3.70 (m, 1H,
O-CH2), 4.19 (t, 1 H, J¼ 7.0 Hz, 15-H), 5.25 (s, 2H, NH2), 6.99 (d, 1H,
J¼ 3.0 Hz, 4-H), 7.02 (dd, 1H, J¼ 10.5 Hz, J¼ 3.0 Hz, 2-H), 7.23 (t,
1 H, J¼ 10.5Hz, 1-H). 13C NMR (d, ppm, CDCl3): 17.9 (C-18), 19.8,
26.0, 26.4, 29.6, 33.0, 34.7, 43.2 (linker CH2), 44.7, 47.6 (C-13), 54.8,
64.7 (OCH2), 75.9 (C-15), 118.3 (CN), 119.5 (C-2), 122.5 (C-4), 127.0
(C-1), 139.3 (C-10), 139.4 (C-5), 148.5 (C-3), 219.3 (C-17).
3-Benzyloxy-15b-(2’-methoxy-2’-oxoethoxy)-estra-1,3,5(10)-trien-
17-one (22)
Compound 7 (717mg, 2mmol) in CH2Cl2 (10ml) and ethane-1,2
diol (15ml), containing 5% aqueous sodium hydroxide (1ml) was
stirred at room temperature for 6 h. The reaction mixture was
diluted with water (100ml). The organic phase was separated,
washed with water, dried and evaporated in vacuo. The crude 3-
benzyloxy-15b-(2’-hydroxy)ethoxy-estra-1,3,5(10)-trien-17-one was
dissolved in acetone (15ml) and Jones reagent (1ml) was added
cooling with ice. The mixture was diluted with ice-water, the pre-
cipitate was filtered off, and dried. The crude 3-benzyloxy-15b-
(carboxyl)methoxy-estra-1,3,5(10)-trien-17-one was dissolved in tet-
rahydrofurane (10ml) and diethyl ether containing 1% diazo-
methane (50ml) was added during cooling with ice. After
standing 6 h, the solution was evaporated and the residue was
chromatographed on silica gel with ethyl acetate/CH2Cl2 (2.5/97.5
v/v) to yield 22 (265mg, 29%). Mp: 101–103 C; Rf¼ 0.55 (ss C);
[a]D
25 þ 71 (c 1 in CHCl3). Found: C, 75.12; H, 7.35. C28H32O5
(448.55) requires: C, 74.97; H, 7.19%. 1H NMR (d, ppm, CDCl3): 1.21
(s, 3H, 18-H3), 2.93 (m, 2H, 6-H2), 3.76 (s, 3H, COOCH3), 4.10 (m,
2H, O-CH2), 4.36 (t, 1 H, J¼ 6.5 Hz, 15-H), 5.05 (s, 2H, Bn-H2), 6.99
(s, 1H, 4-H), 6.76 (d, 1H, J¼ 3.5 Hz, 2-H), 7.21 (d, 1H, J¼ 10.5 Hz, 1-
H), 7.38 (m, 5H, 5x CH of Bn). 13C NMR (d, ppm, CDCl3): 16.9 (C-
18), 25.2, 25.6, 29.0, 32.3, 34.3, 42.4, 43.9, 46.8 (C-13), 51.2, 54.1
(OCH3), 66.0 (O-CH2), 69.5 (Bn-CH2), 75.2 (C-15), 111.8 (C-2), 114.5
(C-4), 125.6 (C-1), 126.9 (C-2 and C-6 of Bn), 127.3 (C-4-of Bn),
128.0 (C-3 and C-5 of Bn), 131.9 (C-10), 136.9 (C-1’), 137.5 (C-5),
156.4 (C-3), 170.2 (C¼O), 218.4 (C-17).
3-Methoxy-15b-(3’-methoxy-3’-oxopropoxy)-estra-1,3,5(10)-trien-
17-one (23)
Compound 14 (373mg, 1mmol) was dissolved in tetrahydrofuran
(10ml) and diethylether containing 1% diazomethane (50ml) was
added during cooling with ice. After standing 6 h, the solution
was evaporated and the residue was crystallized from MeOH, to
yield 23 (370mg, 95%). Mp: 95–97 C; Rf¼ 0.58 (ss C); [a]D25 þ 64
(c 1 in CHCl3). Found: C, 71.62; H, 8.04; C23H30O5 (386.48) requires:
C, 71.48; H, 7.82%. 1H NMR (d, ppm, CDCl3): 1.13 (s, 3H, 18-H3),
2.40 (m, 2H, linker H2), 2.90 (m, 2H, 6-H2), 3.59 (m, 2H, linker H2)
3.69 (s, 3H, 3-OCH3), 3.80 (s, 3H, COOCH3), 4.20 (t, 1 H, J¼ 6.5 Hz,
15-H), 6.68 (s, 1H, 4-H), 6.74 (dd, 1H, J¼ 10.5Hz, J¼ 3.0 Hz, 2-H),
7.21 (d, 1H, J¼ 10.5 Hz, 1-H). 13C NMR (d, ppm, CDCl3): 17.8 (C-18),
26.2, 26.6, 30.0, 33.2, 35.2, 35.6, 43.3, 44.6 (linker CH2), 47.7 (C-13),
52.1, 54.9, 55.6 (3-OCH3), 65.3 (O-CH2), 75.3 (C-15), 111.9 (C-2),
114.3 (C-4), 126.6 (C-1), 132.6 (C-10), 138.3 (C-5), 158.1 (C-3), 172.4
(C¼O), 219.9 (C-17).
3-Hydroxy-15b-(3’-methoxy-3’-oxopropoxy)-estra-1,3,5(10)-trien-17-
one (24)
Compound 15 (448mg, 1mmol) was dissolved in tetrahydrofuran
(10ml) and diethyl ether containing 1% diazomethane (50ml) was
added during cooling with ice. After standing 6 h, the solution
was evaporated and the residue was crystallized from MeOH, to
yield crude 3-benzyloxy-15b-(3’-methoxy-3’-oxopropoxy)-estra-
1,3,5(10)-trien-17-one. This compound was dissolved in ethyl acet-
ate (30ml) and the solution containing Pd/C (300mg, 10%) was
hydrogenated under 5 bar pressure for 6 h, at room temperature.
The reaction mixture was filtered off, evaporated in vacuo and the
residue was chromatographed on silica gel with ethyl acetate/
CH2Cl2 (10:90 v/v) to yield 24 (196mg, 52%). Mp: 140–142 C;
Rf¼ 0.25 (ss A); [a]D20 þ 51 (c 1 in CHCl3). Found: C, 71.08; H, 7.76.
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C22H28O5 (372.45) requires: C, 70.94; H, 7.58%.
1H NMR (d, ppm,
DMSO-d6): 0.99 (s, 3H, 18-H3), 2.75 (m, 2H, 6-H2), 3.34 (s, 4H, 2 x
linker H2), 3.58 (s, 3H, COO-H3), 4.13 (t, 1 H, J¼ 6.5 Hz, 15-H), 6.48
(s, 1H, 4-H), 6.52 (dd, 1H, J¼ 10.5 Hz, J¼ 3.0 Hz, 2-H), 7.04 (d, 1H,
J¼ 10.5Hz, 1-H), 8.99 (brs, 1H, 3-OH). 13C NMR (d, ppm, DMSO-d6):
18.0 (C-18), 26.3, 26.5, 29.9, 33.2, 35.6, 35.6, 43.4 (linker CH2), 44.4,
47.4 (C-13), 52.1, 54.0, 65.3 (O-CH2), 75.2 (C-15), 113.6 (C-2), 115.9
(C-4), 126.8 (C-1), 131.0 (C-10), 138.0 (C-5), 155.9 (C-3), 172.6
(C¼O), 219.7 (C-17).
General procedure for the synthesis of 3-hydroxy-, and 3-
benzyloxy-15b-(carboxamido)alkoxy-estra-1,3,5(10)-trienes with
ammonium hydroxide, morpholine or N-cyclohexyl,N-
methylamine (25–33)
To the solution of the corresponding 3-hydroxy-, or 3-benzyloxy-
15b-(carboxyl)alkoxy-estra-1,3,5(10)-triene (1mmol) in CH2Cl2
(20ml) 0.2ml (2mmol) oxalyl chloride was added dropwise while
cooling in ice under continuous stirring. The solution was allowed
to stand at room temperature for 2 h. After evaporation in vacuo
the residue was dissolved in CH2Cl2 (20ml) and 4mmol of the cor-
responding amine component was added while cooling in ice
under continuous stirring. After 1 h, water (100ml) was added and
extracted with CH2Cl2 (2x 50ml). The organic phase was washed
with water, dried and evaporated. The residual material was chro-
matographed on a silica gel column with ethyl acetate/CH2Cl2 in
different concentrations.
3-Benzyloxy-15b-(3’-amino-3-oxopropoxy)-estra-1,3,5,(10)-trien-17-
one (25)
Compound 15 (448mg, 1mol) was used for synthesis as described
in general procedure. The amine component was ammonium
hydroxide solution (20ml). The crude product was chromato-
graphed on silica gel with ethyl acetate/CH2Cl2 (1:1 v/v) to yield
22 (238mg, 53%). Mp: 183–185 C; Rf¼ 0.55 (ss C); [a]D25 þ 61 (c
1 in CHCl3). Found: C, 75.36; H, 7.26. C28H33NO4 (447.57) requires:
C, 75.14; H, 7.43%. 1H NMR (d, ppm, CDCl3): 1.26 (s, 3H, 18-H3),
2.30 (m, 2H, linker H2), 2.96 (m, 2H, 6-H2),3.60 (m, 2H, linker H2),
4.43 (t, 1 H, J¼ 6.0 Hz, 15-H), 5.07 (s, 2H, Bn-H2), 6.78 (s, 1H, 4-H),
6.83 (dd, 1H, J¼ 10.5Hz, J¼ 3.0 Hz, 2-H), 7.24 (d, 1H, J¼ 10.5 Hz, 1-
H), 7.38 (m, 5H, 5x CH of Bn). 13C NMR (d, ppm, CDCl3): 15.5 (C-
18), 22.0, 23.9, 24.2, 27.8, 30.9, 33.2, 33.8, 40.9, 41.9 (linker CH2),
45.9 (C-13), 50.1, 51.8, 64.7 (linker CH2), 73.9 (C-15), 112.2 (C-2),
114.6 (C-2), 125.8 (C-1), 123.0 (C-10), 126.8 (C-2 and C-6 of Bn),
127.1 (C-4 of Bn), 129.0 (C-3 and C-5 of Bn), 137.4 (C-5), 155.8 (C-
3), 171.8 (C¼O), 220.1 (C-17).
3-Hydroxy-15b-(3’-amino-3’-oxopropoxy)-estra-1,3,5(10)-trien-17-
one (26)
Compound 25 (448mg, 1mmol) was dissolved in ethyl acetate
(30ml) and the solution containing Pd/C (300mg, 10%) was
hydrogenated under 5 bar pressure for 6 h, at room temperature.
The reaction mixture was filtered off and evaporated in vacuo. The
residue was chromatographed on silica gel column with ethyl
acetate/CH2Cl2 (1:1 v/v) to yield 26 (308mg, 86%). Mp:
124–126 C; Rf¼ 0.20 (ss A); [a]D25 þ 54 (c 1 in MeOH). Found: C,
70.38; H, 7.85. C21H27NO4 (357.44) requires: C, 70.56; H, 7.61%.
1H
NMR (d, ppm, DMSO-d6): 1.03 (s, 3H, 18-H3), 2.77 (m, 2H, 6-H2),
3.33 (s, 2H, linker H2), 3.47 (m, 1H, O-CH2), 3.68 (m, 1H, O-CH2),
4.11 (t, 1 H, J¼ 6.5 Hz, 15-H), 6.47 (d, 1H, J¼ 3.5 Hz, 4-H), 6.52 (dd,
1H, J¼ 10.5 Hz, J¼ 3.5 Hz, 2-H), 6.78 (brs, 1H, NH2), 7.04 (d, 1H,
J¼ 10.5 Hz, 1-H), 7.22 (brs, 1H, NH2), 7.90 (brs, 1H, 3-OH). 13C NMR
(d, ppm, DMSO-d6): 16.5 (C-18), 24.7, 24.9, 28.3, 31.7, 34.0, 35.3,
42.0, 42.8 (linker CH2), 45.8 (C-13), 52.5, 64.4 (linker CH2), 73.5 (C-
15), 112.0 (C-2), 114.2 (C-2), 125.1 (C-1), 129.5 (C-10), 136.5 (C-5),
154.3 (C-3), 171.6 (C¼O), 218.3 (C-17).
3-Benzyloxy-15b-(2’-morpholino-2’-oxoethoxy-estra-1,3,5(10)-trien-
17-one (27)
3-Benzyloxy-15b-(carboxyl)methoxy-estra-1,3,5(10)-triene (434mg,
1mmol) was used for the synthesis as described in general pro-
cedure. The crude steroidal carbonyl chloride was dissolved in
CH2Cl2 (20ml), and morpholine (0.35ml, 4mmol) was added drop-
wise during cooling with ice under continuous stirring. After 1 h,
water (100ml) was added, and extracted with CH2Cl2 (2 x 50ml).
The organic solution was washed with water, dried, and evapo-
rated. The residual material was chromatographed on silica gel
column with ethyl acetate/CH2Cl2 (25:75 v/v) to yield 27 (432mg,
85%). Mp: 121–123 C; Rf¼ 0.45 (ss D); [a]D25 þ 37 (c 1 in MeOH).
Found: C, 74.14; H, 7.53. C31H37NO5 (503.63) requires: C, 73.93; H,
7.41%. 1H NMR (d, ppm, CDCl3): 1.16 (s, 3H, 18-H3), 3.58 (m, 8H, 4x
morpholine H2), 4.08 (d, 1H, J¼ 13.0Hz, O-CH2), 4.20 (d, 1H,
J¼ 13.0 Hz, O-CH2), 4.35 (t, 1 H, J¼ 5.5 Hz, 15-H), 5.04 (s, 2H, Bn-
H2), 6.75 (s, 1H, 4-H), 6.80 (dd, 1H, J¼ 8.5 Hz, J¼ 2.5 Hz, 2-H), 7.20
(d, 1H, J¼ 8.5 Hz, 1-H), 7.32 (t, 1H, J¼ 7.5 Hz, Bn 4-H), 7.38 (t, 2H,
J¼ 7.5 Hz, Bn 3- and 5-H), 7.43 (d, 2H, J¼ 7.5 Hz, Bn-2- and 6-H).
13C NMR (d, ppm, CDCl3): 17.5 (C-18), 25.6, 26.3, 29.5, 32.7, 34.8,
42.1, 43.0, 44.3, 45.9 (C-13), 47.2, 54.4, 66.7 (morpholine CH2), 66.7
(morpholine CH2), 69.1 (O-CH2), 69.9 (Bn-CH2), 76.0 (C-15), 112.4
(C-2), 114.8 (C-4), 126.2 (C-1), 127.4 (C-2 and C-6 of Bn), 127.8 (C-4
of Bn), 128.5 (C-3 and C-5 of Bn), 132.1 (C-10), 137.1 (C-1 of Bn),
137.5 (C-5), 156.9 (C-3), 167.5 (C¼O), 218.7 (C-17).
3-Hydroxy-15b-(carboxmorpholydo)methoxy-2’-morpholino-2’oxoe-
thoxy)-estra-1,3,5(10)-trien-17-one (28)
Compound 27 (503mg, 1mmol) was dissolved in ethyl acetate
(30ml) and the solution containing Pd/C (448mg, 10%) was
hydrogenated under 5 bar pressure for 6 h at room temperature.
The reaction mixture was filtered off, evaporated in vacuo, and
the residue was crystallized from MeOH to yield 28 (350mg, 69%).
Mp: 215–220 C; Rf¼ 0.40 (ss D); [a]D25 þ 54 (c 1 in MeOH).
Found: C, 73.07; H, 7.92. C25H33NO4 (411.53) requires: C, 72.96; H,
8.08%. 1H NMR (d, ppm, CDCl3): 1.14 (s, 3H, 18-H3), 3.51 (s, 2H,
linker H2), 3.58 (m, 2H, 2x H2 of morpholine), 3.60 (m 2H, 2x H2 of
morpholine), 4.14 (t, 1 H, J¼ 6.5 Hz, 15-H), 6.60 (d, 1H J¼ 2.5 Hz, 4-
H), 6.65 (dd, 1H, J¼ 10.5 Hz, J¼ 3.0 Hz, 2-H), 7.12 (d, 1H,
J¼ 10.5 Hz, 1-H). 13C NMR (d, ppm, CDCl3): 18.0 (C-18), 26.0, 26.2,
26.7, 29.9, 30.1, 33.1, 35.4, 42.5, 43.7, 44.5, 46.4, 47.7 (C-13), 54.9,
66.6 (linker CH2), 67.3 (linker CH2), 75.2 (C-15), 113.4 (C-2), 115.8
(C-4), 126.7 (C-1), 132.1 (C-10), 138.2 (C-5), 154.2 (C-1), 172.0 (linker
C¼O), 220.5 (C-17).
3-Benzyloxy-15b-(3’-morpholino-3’oxopropoxy)-estra-1,3,5(10)-
trien-17-one (29)
Compound 15 (448mg, 1mmol) was used for synthesis as
described in general procedure. The crude steroidal carbonyl
chloride was dissolved in CH2Cl2 (20ml), and morpholine (0.35ml,
4mmol) was added dropwise during cooling with ice under con-
tinuous stirring. After 1 h, water (100ml) was added, and extracted
with CH2Cl2 (2x 50ml). The organic solution was washed with
water, dried, and evaporated. The residual material was
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 1275
chromatographed on silica gel column with ethyl acetate/CH2Cl2
(2.5:97.5 v/v) to yield 29 (372mg, 72%). Mp: 128–130 C; Rf¼ 0.42
(ss D); [a]D
25 þ 37 (c 1 in CHCl3). Found: C, 74.46; H, 7.72.
C32H39NO5 (517.66) requires: C, 74.24; H, 7.59%.
1H NMR (d, ppm,
CDCl3): 1.12 (s, 3H, 18-H3), 2.89 (m, 2H, 6-H2), 3.51(m, 2H, linker
H2), 4.20 (t, 1H, J¼ 6.5 Hz, 15-H), 5.04 (s, 2H, Bn-H2), 6.74 (d, 1H,
J¼ 3.5 Hz, 4-H), 6.79 (dd, 1H, J¼ 10.5Hz, J¼ 3.5 Hz, 2-H), 7.19 (d,
1H, J¼ 10.5Hz, 1-H), 7.31 (t, 1 H, J¼ 8.5 Hz, Bn 4-H), 7.38 (t, 2H,
J¼ 8.5 Hz, Bn 3- and 5-H), 7.43 (d, 2H, J¼ 8.5 Hz, Bn 2- and 6-H).
13C NMR (d, ppm, CDCl3): 17.9 (C-18), 26.2, 26.6, 30.0, 33.1, 33.7,
35.4, 42.4 (morpholine CH2), 43.5 (linker CH2), 44.6, 46.5 (morpho-
line CH2), 47.7 (C-13), 54.9, 66.2 (O-CH2), 67.1 (morpholine CH2),
67.3 (morpholine CH2), 70.4 (Bn-CH2), 75.5 (C-15), 112.8 (C-2),
115.4 (C-4), 126.6 (C-1), 127.8 (C-2 and C-6 of Bn), 128.3 (C-4 of
Bn), 129.0 (C-3 and C-5 of Bn), 132.9, 137.9 (C-1’), 138.2 (C-5),
157.3 (C-3), 169.9 (C¼O), 219.9 (C-17).
3-Sulfamoyloxy-15b-(3’-morpholino-3’-oxopropoxy)-estra-1,3,5(10)-
trien-17-one (30)
Compound 29 (517mg, 1mmol) was dissolved in ethyl acetate
(30ml) and the solution containing Pd/C (300mg, 10%) was
hydrogenated under 5 bar pressure for 6 h, at room tempera-
ture. The reaction mixture was filtered off and evaporated in
vacuo. The residue was dissolved in dimethylformamide (20ml),
and 575mg (5mmol) sulfamoyl chloride was added dropwise
during cooling with ice. The reaction mixture was allowed to
stand 6 h and then poured onto ice (300 g). The precipitate sep-
arated out was filtered off, and subjected to chromatographic
separation on silica gel column with ethyl acetate/CH2Cl2 (1:1 v/
v) to yield 30 (240mg, 45%). Mp: 104–108 C; Rf¼ 0.35 (ss D);
[a]D
25 þ 17 (c 1 in CHCl3). Found: C, 59.43; H, 6.54.
C25H34N2O7S (506.61) requires: C, 59.27; H, 6.76%.
1H NMR (d,
ppm, CDCl3): 1.12 (s, 3H, 18-H3), 2.74 (m, 2H, linker CH2), 4.46
(m, 4H, 2x H2 of morpholine), 3.56 (m, 2H, O-CH2), 3.61 (m, 4H,
2x H2 of morpholine), 3.82 (t, 1 H, J¼ 6.5 Hz, 15-H), 5.42 (s, 2H,
NH2), 6.78 (d, 1H, J¼ 3.5 Hz, 4-H), 7.20 (dd, 1H, J¼ 10.0Hz,
J¼ 3.5 Hz, 2-H), 7.30 (t, 1 H, J¼ 10.0 Hz, 1-H). 13C NMR (d, ppm,
CDCl3): 17.8 (C-18), 26.1, 26.7, 30.5, 33.4, 33.9, 35.5, 42.2 (mor-
pholine CH2), 43.4 (linker CH2), 45.1, 46.7 (morpholine CH2), 47.5
(C-13), 55.8, 64.3 (O-CH2), 66.7 (morpholine CH2), 67.5 (morpho-
line CH2), 75.7 (C-15), 112.5 (C-2), 115.1 (C-4), 126.8 (C-1), 133.0,
140.5 (C-5), 159.1 (C-3), 170.9 (C¼O), 220.2 (C-17).
3-Benzyloxy-15b-(4’-morpholino-4’oxobutoxy)-estra-1,3,5(10)-trien-
17-one (31)
Compound 17 (462mg, 1mmol) was used for the synthesis as
described in general procedure. The crude steroidal carbonyl
chloride was dissolved in CH2Cl2 (20ml), and morpholine (0.35ml,
4mmol) was added dropwise during cooling with ice under con-
tinuous stirring. After 1 h, water (100ml) was added, and extracted
with CH2Cl2 (2 x 50ml). The organic solution was washed with
water, dried and evaporated in vacuo. The residual material was
chromatographed on silica gel column with ethyl acetate/CH2Cl2
(30:70 v/v) to yield 31 (810mg, 76%). Mp: 135–138 C; Rf¼ 0.42
(ss D); [a]D
25 þ 20 (c 1 in CHCl3). Found: C, 74.87; H, 7.43.
C33H41NO5 (531.68) requires: C, 74.55; H, 7.77%.
1H NMR (d, ppm,
CDCl3): 1.14 (s, 3H, 18-H3), 1.91 (m, 4H, 2 x morpholine H2), 2.37
(m, 4H, 2 x morpholine H2), 3.36 (t, 2H, J¼ 6.5 Hz, O-CH2), 4.15 (t,
1 H, J¼ 6.5 Hz, 15-H), 5.04 (s, 2H, Bn-H2), 6.73 (d, 1H, J¼ 3.5 Hz, 4-
H), 6.79 (dd, 1H, J¼ 10.5Hz, J¼ 3.5 Hz, 2-H), 7.20 (d, 1H,
J¼ 10.5Hz, 1-H), 7.36 (m, 5H, 5x CH of Bn). 13C NMR (d, ppm,
CDCl3): 18.0 (C-18), 26.0, 26.2, 26.7, 30.0, 33.1, 34.7, 35.4, 42.3 (mor-
pholine CH2), 43.7 (linker CH2), 44.6, 46.3 (morpholine CH2), 47.7
(C-13), 54.9, 67.0 (morpholine CH2), 67.3 (morpholine CH2), 69.0
(O-CH2), 70.4 (Bn-CH2), 75.1 (C-15), 112.8 (C-2), 115.4 (C-4), 126.6
(C-1), 127.8 (C-2 and C-6 of Bn), 128.3 (C-4’), 129.0 (C-3 and C-5 of
Bn), 132.9 (C-10), 137.9 (C-1 of Bn), 138.1 (C-5), 157.4 (C-3), 171.6
(C¼O), 220.0 (C-17).
3-Hydroxy-15b-(4’-morpholino-4’-oxobutoxy)-estra-1,3,5(10)-trien-
17-one (32)
Compound 31 (531mg, 1mmol) was dissolved in ethyl acetate
(30ml) and the solution containing Pd/C (300mg, 10%) was
hydrogenated under 5 bar pressure for 6 h, at room temperature.
The reaction mixture was filtered off, evaporated in vacuo and
crystallized from MeOH to yield 32 (390mg, 88%). Mp: 80–84 C;
Rf¼ 0.35 (ss D); [a]D25 þ 46 (c 1 in CHCl3). Found: C, 70.58; H, 8.12.
C26H35NO5 (441.57) requires: C, 70.72; H, 7.99%.
1H NMR (d, ppm,
CDCl3): 1.14 (s, 3H, 18-H3), 3.33 (t, 2H, J¼ 6.0 Hz, linker H2), 3.48
(m, 4H, 2x morpholine H2), 361 (m, 4H, 2x morpholine H2), 4.14 (t,
1 H, J¼ 6.5 Hz, 15-H), 6.60 (d, 1H J¼ 2.5 Hz, 4-H), 6.65 (dd, 1H,
J¼ 10.5 Hz, J¼ 3.0 Hz, 2-H), 7.12 (d, 1H, J¼ 10.5 Hz, 1-H). 13C NMR
(d, ppm, CDCl3): 18.0 (C-18), 26.0, 26.2, 26.7, 29.9, 30.1, 33.1, 35.4,
42.5, 43.7, 44.5, 46.4, 47.7 (C-13), 54.9, 66.6 (linker CH2), 67.3 (linker
CH2), 69.0 (linker CH2), 75.2 (C-15), 113.4 (C-2), 115.8 (C-4), 126.7
(C-1), 132.1 (C-10), 138.2 (C-5), 154.2 (C-1), 172.0 (linker C¼O),
220.5 (C-17).
3-Methoxy-15b-(2’N-cyclohexyl,N-methyl-2’oxoethoxy)-estra-
1,3,5(10)-trien-17-one (33)
Starting from 3-methoxy-15b-(carboxyl)methoxy-estra-1,3,5(10)-
trien-17-one (13) 358mg (1mmol) was used for synthesis as
described in general procedure. The crude steroidal carbonyl
chloride was dissolved in CH2Cl2 (20ml), and N-cyclohexyl, N-
methylamine (4.5ml, 4mmol) was added dropwise during cooling
with ice under continuous stirring. After 1 h, water (100ml) was
added, and extracted with CH2Cl2 (2 x 50ml). The organic solution
was washed with water, dried, and evaporated. The residual
material was chromatographed on silica gel column with ethyl
acetate/CH2Cl2 (25:75 v/v) to yield 33 (385mg, 84%). Mp:
53–58 C (foam); Rf¼ 0.50 (ss B); [a]D25 þ 61 (c 1 in CHCl3). Found:
C, 73.92; H, 8.82. C28H39NO4 (453.61) requires: C, 74.14; H, 8.67%.
1H NMR (d, ppm, CDCl3): 1.18 (s, 3H, 18-H3), 3.30 (s, 3H, N-CH3),
3.77 (s, 3H, 3-OCH3), 4.12 (m, 2H, O-CH2), 4.39 (m, 1H, 15-H), 6.65
(s, 1H, 4-H), 6.71 (d, 1H, J¼ 11.0Hz, 2-H), 7.19 (d, 1H, J¼ 11.0 Hz,
1-H). 13C NMR (d, ppm, CDCl3): 17.9 (C-18), 25.8, 26.0, 26.2, 27.6,
29.3, 29.9, 30.0, 31.3, 33.2, 35.4, 43.5, 43.8 (C-13), 44.8, 47.7, 53.0,
55.0, 55.6, 69.9 (O-CH2), 75.7 (C-15), 112.0 (C-2), 114.3 (C-4), 126.6
(C-1), 132.5 (C-10), 138.1 (C-5), 158.1 (C-3), 166.3 (C¼O), 219.5
(C-17).
General procedure for the synthesis of 3-benzyloxy-15b-
(carbamoyloxy)alkoxy-estra-1,3,5(10)-trien-17-one (34–40)
To the solution of 3-benzyloxy-15b-(2’-hydroxy)ethoxy-estra-
1,3,5(10)-trien-17-one (10) or 3-benzyloxy-15b-(3’-hydroxy)propoxy-
estra-1,3,5(10)-trien-17-one (11) mmol) in CH2Cl2 (30ml) contain-
ing 0.2ml triethylamine, 4mmol of the corresponding alkyl or aryl
isocyanate was added under continuous stirring. After the add-
ition of the reagent the reaction mixture was heated at reflux for
1 h, poured into water (100ml), and then extracted with CH2Cl2
(2x 30ml). The organic phase was washed with NaHCO3 solution,
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water, dried and evaporated in vacuo. The residual material was
chromatographed on a silica gel column with ethyl acetate/CH2Cl2
in different concentrations.
3-Benzyloxy-15b-(2’-cyclohexylcarbamoyloxy)ethoxy-estra-
1,3,5(10)-trien-17-one (34)
Compound 10 (420mg, 1mmol) was used for the synthesis as
described in general procedure. The reagent was cyclohexyl iso-
cyanate (4mmol). The crude product was chromatographed with
ethyl acetate/CH2Cl2 (2.5:97.5 v/v) to yield 34 (430mg, 78%). Mp:
96–98 C; Rf¼ 0.55 (ss B); [a]D25 þ 39 (c 1 in CHCl3). Found: C,
74.65; H, 8.14. C34H43NO5 (545.71) requires: C, 74.83; H, 7.94%.
1H
NMR (d, ppm, CDCl3): 1.16 (s, 3H, 18-H3), 3.65 (m, 2H, 16-H2), 3.68
(m, 1H, OCH2), 4.19 (m, 3H, OCH2), 4.55 (d, 1H, J¼ 7.5 Hz, 15-H),
5.03 (s, 2H, Bn-H2), 6.73 (d, 1H, J¼ 3.0 Hz, 4-H), 6.78 (dd, 1H,
J¼ 10.5Hz, J¼ 3.0 Hz, 2-H), 7.19 (d, 1H, J¼ 10.5 Hz, 1-H), 7.37 (m,
5H, 5x CH of Bn). 13C NMR (d, ppm, CDCl3): 17.9 (C-18), 24.8, 25.2,
25.9, 26.2, 30.0, 33.2, 33.8, 35.2, 43.7 (O-CH2), 44.6, 47.8 (C-13),
50.2, 53.8, 55.0, 64.0, 68.3 (O-CH2), 70.4, 70.5 (Bn-CH2), 75.4 (C-15),
112.7 (C-2), 115.4 (C-4), 126.6 (C-1), 127.8 (C-2 and C-6 of Bn),
127.8 (C-4 of Bn), 129.0 (C-3 and C-5 of Bn), 133.0 (C-10), 137.8 (C-
1’), 138.3 (C-5), 157.3 (C-3), 220.0 (C-17).
3-Hydroxy-15b-(2’-cyclohexylcarbamoyloxy)ethoxy-estra -1,3,5(10)-
trien-17-one (35)
Compound 34 (545mg, 1mmol) was dissolved in ethyl acetate
(30ml) and the solution containing Pd/C (300mg, 10%) was
hydrogenated under 5 bar for 6 h, at room temperature. The reac-
tion mixture was filtered off and evaporated in vacuo. The residual
material was chromatographed on silica gel column with ethyl
acetate/CH2Cl2 (25:75 v/v) to yield 35 (390mg, 85%). Mp:
95–96 C; Rf¼ 0.40 (ss D); [a]D25 þ 51 (c 1 in CHCl3). Found: C,
71.37; H, 8.02. C27H37NO5 (455.60) requires: C, 71.18; H, 8.19%.1H
NMR (d, ppm, CDCl3): 1.12 (s, 3H, 18-H3), 1. 22 (m, 4H, 2x H2 of
cyclohexyl), 1. 56 (m, 4H, 2x H2 of cyclohexyl), 3.62 (m, 2H, 16-H2),
3.66 (m, 2H, O-CH2), 4.28 (m, 2H, O-CH2), 4.55 (d, 1H, J¼ 7.5 Hz,
15-H), 6.61 (d, 1H, J¼ 3.0 Hz, 4-H), 6.71 (dd, 1H, J¼ 10.5Hz,
J¼ 3.0 Hz, 2-H), 7.10 (d, 1H, J¼ 10.5 Hz, 1-H). 13C NMR (d, ppm,
CDCl3): 17.9 (C-18), 24.6, 25.4, 25.9, 25.9, 26.1, 30.1, 33.3, 33.7, 35.4,
44.1 (O-CH2), 44.8, 48.9 (C-13), 50.4, 54.0, 55.0, 64.2, 68.4 (O-CH2),
70.5, 75.6 (C-15), 112.7 (C-2), 115.5 (C-4), 126.8 (C-1), 133.3 (C-10),
138.6 (C-5), 157.5 (C-3), 220.0 (C-17).
3-Benzyloxy-15b-(2’-t-butylcarbamoyloxy)ethoxy-estra-1,3,5(10)-
trien-17-one (36)
Compound 10 (420mg, 1mmol) was used for the synthesis as
described in general procedure. The reagent was t-butyl isocyan-
ate (4mmol). The crude product was chromatographed with ethyl
acetate/CH2Cl2 (2.5:97.5 v/v) to yield 36 (265mg, 51%). Mp:
206–207 C; Rf¼ 0.45 (ss B); [a]D25 þ8 (c 1 in CHCl3). Found: C,
73.82; H, 8.15. C32H41NO5 (519.67) requires: C, 73.95; H, 7.95%.1H
NMR (d, ppm, CDCl3): %)
1H NMR (d, ppm, CDCl3): 1.15 (s, 3H, 18-
H3), 1.42 (s, 9H, t-Bu), 3.62 (m, 2H, O-CH2), 3.81 (m, 2H, O-CH2),
4.21 (t, 1 H, J¼ 7.0 Hz, 15-H), 5.12 (s, 2H, Bn-H2), 6.62 (d, 1H,
J¼ 3.5 Hz, 4-H), 6.80 (dd, 1H, J¼ 11.0Hz, J¼ 3.5 Hz, 2-H), 7.19 (d,
1H, J¼ 11.0 Hz, 1-H), 7.40 (m, 5 H, 5x CH of Bn). 13C NMR (d, ppm,
CDCl3): 13 C NMR (d, ppm, CDCl3): 18.2 (C-18), 26.0, 26.5, 29.3 (3 x
CH3 of t-Bu), 29.6, 33.0, 35.1, 41.9, 43.9 (O-CH2), 44.7, 48.0 (C-13),
55.0, 56.7 (quaterner C of t-Bu), 64.9 (O-CH2), 67.1 (O-CH2), 70.3
(Bn-CH2), 75.3 (C-15), 112.8 (C-2), 115.2 (C-4), 124.4 (C-1), 126.8 (C-
2 and C-6 of 3-Bn), 128.1 (C-4 of 3-Bn), 129.5 (C-3 and C-5 of 3-
Bn), 133.1 (C-10), 138.0 (C-1 of 3-Bn), 133.5 (C-5), 158.1 (C-3), 220.0
(C-17).
3-Benzyloxy-15b-(2’-phenylcarbamoyloxy)ethoxy-estra-1,3,5(10)-
trien-17-one (37)
Compound 10 (420mg, 1mmol) was used for the synthesis as
described in general procedure. The reagent was phenyl isocyan-
ate (4mmol). The crude product was chromatographed with ethyl
acetate/CH2Cl2 (25:75 v/v) to yield 37 (310mg, 57%). Mp:
73–76 C (foam); Rf¼ 0.65 (ss B); [a]D25 þ 35 (c 1 in CHCl3). Found:
C, 75.83; H, 7.12. C34H37NO5 (539.66) requires: C, 75.67; H, 6.91%
1H NMR (d, ppm, CDCl3): 1.16 (s, 3H, 18-H3), 3.60 (m, 1H, O-CH2),
3.73 (m, 1H, O-CH2), 4.21 (t, 1 H, J¼ 6.5 Hz, 15-H), 4.30 (m, 2H, O-
CH2), 5.02 (s, 2H, Bn-H2), 6.64 (s, 1H, NH), 6.67 (d, 1H, J¼ 3.0 Hz, 4-
H), 6.77 (dd, 1H, J¼ 10.5Hz, J¼ 3.0 Hz, 2-H), 7.06 (t, 1H, J¼ 9.0 Hz,
4H of N-Ph), 7.17 (d, 1H, J¼ 10.5 Hz, 1-H), 7.34 (m, 9H, 5x CH of
Bn and 4x CH of N-Ph). 13C NMR (d, ppm, CDCl3): 18.0 (C-18), 26.2,
26.7, 29.9, 33.2, 35.2, 41.8, 43.7 (O-CH2), 44.6, 47.8 (C-13), 55.0, 64.7
(O-CH2), 68.1 (O-CH2), 70.4 (Bn-CH2), 75.5 (C-15), 112.8 (C-2), 115.4
(C-4), 121.1 (C-4” of N-Ph), 124.1 (C-1), 126.6 (C-2’ and C-6’), 127.9
(C-4’), 128.3 (C-2 and C-6 of 3Bn), 129.0 (C-3 and C-5 of 3Bn),
129.5 (C-3 and C-5 of N-Ph), 132.9 (C-10), 137.7 (C-1 of 3-Bn),
132.8 (C-5), 154.8 (C-1), 157.3 (C-3), 220.0 (C-17).
3-Benzyloxy-15b-(2’-4’’-chlorophenylcarbamoyloxy)ethoxy-estra-
1,3,5(10)-trien-17-one (38)
Compound 10 (420mg, 1mmol) was used for the synthesis as
described in general procedure. The reagent was 4-chlorophenyl
isocyanate (4mmol). The crude product was chromatographed
with ethyl acetate/CH2Cl2 (25:75 v/v) to yield 38 (380mg, 66%).
Mp: 103–106 C; Rf¼ 0.62 (ss B); [a]d25þ 32 (c 1 in CHCl3) . Found:
C, 71.38; H, 6.55. C34H35ClNO5 (574.11) requires: C, 71.13; H, 6.32%.
1H NMR (d, ppm, CDCl3): 1.18 (s, 3H, 18-H3), 3.60 (m, 1H, O-CH2),
3.76 (m, 1H, O-CH2), 4.23 (t, 1 H, J¼ 7.0 Hz, 15-H), 4.33 (m, 2H, O-
CH2), 5.06 (s, 2H, Bn-H2), 6.70 (s, 2H, 4-H, NH), 6.81 (dd, 1H,
J¼ 11.0 Hz, J¼ 3.0 Hz, 2-H), 7.21 (d, 1H, J¼ 11.0 Hz, 1-H), 7.37 (m,
9H, 5x CH of 3-Bn and 6’-H, 4x CH of N-Ph). 13C NMR (d, ppm,
CDCl3): 18.0 (C-18), 26.2, 26.7, 27.5, 29.9, 33.2, 35.2, 42.2, 43.7 (O-
CH2), 44.6, 47.8 (C-13), 55.0, 62.4, 64.8, 68.1 (O-CH2), 70.4 (Bn-CH2),
75.6 (C-15), 112.8 (C-2), 115.3 (C-4), 118.5 (C-4 of 3-Bn), 126.6 (C-1),
127.9 (C-2 and C-6 of 3-Bn), 128.3 (C-2 and C-6 of N-Ph), 129.0 (C-
3 and C-5 of 3-Bn), 129.3 (C-3 and C-5 of N-Ph),129.5 (C-4 of N-
Ph), 157.3 (C-3), 160.1 (C¼O), 219.9 (C-17).
3-Benzyloxy-15b-(3’-butylcarbamoyloxy)propoxy-estra-1,3,5(10)-
trien-17-one (39)
Compound 11 (434mg, 1mmol) was used for the synthesis as
described in general procedure. The reagent was n-butyl isocyan-
ate (4mmol). The crude product was chromatographed with ethyl
acetate/CH2Cl2 (2.5:97.5 v/v) to yield 39 (460mg, 86%). Mp:
101–103 C; Rf¼ 0.40 (ss B); [a]D25 þ 58 (c 1 in CHCl3). Found: C,
74. 43; H, 8.39. C33H43NO5 (533.70) requires: C, 74.27; H, 8.12%).
1H
NMR (d, ppm, CDCl3): 0.88 (t, 3H, J¼ 6.5 Hz, (CH2)3-H3), 11.1 (s, 3H,
18-H3, 2.88 (m, 2H, 6-H2), 3.12 (d, 1H, J¼ 8.0 Hz, NH-CH2), 3.29 (m,
1H, O-CH2), 3.55 (m, 1H, O-CH2), 4.09 (m, 3H, O-CH2, 15-H), 4.57
(brs, 1H, NH), 4.99 (s, 2H, Bn-H2), 6.70 (d, 1H, J¼ 3.0 Hz, 4-H), 6.74
(dd, 1H, J¼ 11.0 Hz, J¼ 3.0 Hz, 2-H), 7.15 (d, 1H, J¼ 11.0 Hz, 1-H),
7.33 (m, 5H, 5x CH of Bn). 13C NMR (d, ppm, CDCl3): 13.6 (CH2)3-
CH3), 17.4 (C-18), 19.7, 25.6, 26.2, 29.4, 29.6, 31.9, 32.6, 34.7, 40.6,
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43.0, 44.1, 47.1 (C-13), 54.4, 61.7 (O-CH2), 65.7 (O-CH2), 69.8 (Bn-
CH2), 74.6 (C-15), 112.2 (C-2), 114.8 (C-4), 126.0 (C-1), 127.3 (C-2
and C-6 of Bn), 127.7 (C-4 of Bn), 128.4 (C-3 and C-5 of Bn), 132.4
(C-10), 137.2 (C-1 of Bn), 137.7 (C-5), 156.4 (C¼O), 156.8 (C-3),
219.5 (C-17).
3-Hydroxy-15b-(3’-n-butylcarbamoyloxy)propoxy-estra-1,3,5(10)-
trien-17-one (40)
Compound 39 (533mg, 1mmol) was dissolved in ethyl acetate
(30ml) and the solution containing Pd/C (300mg, 10%) was
hydrogenated under 5 bar for 6 h, at room temperature. The reac-
tion mixture was filtered off and evaporated in vacuo. The residual
material was chromatographed on silica gel column with ethyl
acetate/CH2Cl2 (25:75 v/v) to yield 40 (290mg, 65%). Mp:
65–70 C (foam); Rf¼ 0.42 (ss D); [a]D25 þ 63 (c 1 in CHCl3). Found:
C, 70.27; H, 8.63. C26H37NO5 (443.58) requires: C, 70.40; H, 8.41%.
1H NMR (d, ppm, CDCl3): 0.91 (s, 3H, J¼ 6.5 Hz, NH-(CH2)2-H3), 1.15
(s, 3H, 18-H3), 3.13 (m, 2H, 6-H2), 3.20 (t, 2H, J¼ 6.5 Hz, N-H2) , 3.33
(t 2H, J¼ 6.0 Hz, linker H2) 4.75 (s, 1H, 15-H), 6.17 (s, 1H, 4-H), 6.64
(dd, 1H, J¼ 10.5Hz, J¼ 3.5 Hz, 2-H), 7.11 (d, 1H, J¼ 10.5 Hz, 1-H).
13C NMR (d, ppm, CDCl3): 11.6 (NH-(CH2)2-CH3), 13.9, 18.0 (C-18),
23.6, 26.2, 26.7, 29.8, 30.1, 33.1, 35.3, 43.2 (C-13), 43.6 (linker CH2),
44.6, 47.8 (linker CH2), 55.0, 62.5 (linker CH2), 66.2 (linker CH2),
75.2 (C-15), 113.3 (C-2), 115.8 (C-4), 126.6 (C-1), 132.1 (C-10), 138.4
(C-5), 154.5 (C-3), 220.8 (C-17).
Measurement of inhibition of 17b-HSD1
Our previously published methods were used for the measure-
ment of 17b-HSD1 inhibition21,22. In brief, human placental cytosol
was incubated as enzyme source with 1 lM [3H]-labelled estrone
substrate at 37 C. The cofactor, either NADH or NADPH, was used
in an excess concentration of 100 lM. The buffer medium con-
sisted of 0.1M HEPES (pH ¼ 7.3), 1mM EDTA, and 1mM dithio-
treitol. The substrate was added to the incubate in 10 ll of a 25 v/
v% propylene glycol in HEPES buffer solution, whereas test com-
pounds were applied in 10ll of dimethyl sulfoxide solution.
After an incubation time of 2.5min, the enzymatic reaction was
stopped and the product 17b-estradiol was isolated by TLC.
Radioactivity of the 17b-estradiol (2) formed was measured by
means of liquid scintillation counting. Test compounds were usu-
ally applied in 10 lM concentration, whereas concentrations of
0.1–50mM were used during determination of IC50 values. The
inhibitor effect was assessed with relative conversion results calcu-
lated in comparison to non-inhibited controls (100%). IC50 results
were calculated by using unweighted iterative least squares logis-
tic curve fitting by means of the “absolute IC50 calculation” func-
tion of the GraphPad Prism 4.0 (GraphPad Software, Inc., San
Diego, CA, USA). The IC50 of unlabelled estrone (1) was measured
as reference. The relative inhibitory potential (RIP) values of the
test compounds were calculated by using reference IC50 data
measured with the corresponding cofactor: RIP¼ IC50 of test com-
pound/IC50 of unlabelled estrone (1).
Results and discussion
Synthetic studies
To prepare novel substituted 15b-alkoxy steroids, 3-methoxy-estra-
1,3,5(10),15-tetraen-17-one (6), and 3-benzyloxy-estra-1,3,5(10),15-
tetraen-17-one (7) were chosen as starting compounds12,23. The
synthetic strategy for the preparation of the different type of com-
pounds is illustrated in Scheme 2.
Treatment of D15-17-one compound 6 with aqueous potassium
hydroxyde in methanol afforded 3,15b-dimethoxy-estra-1,3,5(10)-
trien-17-one via 1,4 addition in practically quantitative yield. On
the basis of an earlier observation from W. S. Johnson and W. F.
Johns23, we extended this 1,4-addition process to 1,2-ethanediol,
1,3-propanediol and 1,4-butanediol to receive from compound 6
the corresponding 3-methoxy-15b-(2’-hydroxy)ethoxy-, and 3-
methoxy-15b-(3’-hydroxy)propoxy-estra-1,3,5(10)-triene-17-ones (8
and 9), from compound 7 the 3-benzyloxy-15b-(2’-hydroxy)ethoxy-
, 3-benzyloxy-15b-(3’-hydroxy)propoxy-, and 3-benzyloxy-15b-(4’-
hydroxy)butoxy-estra-1,3,5(10)-trien-17-ones (10–12). The addition
of different nucleophiles is highly stereospecific, giving 15b substi-
tuted estranes in all cases12,23. Jones oxidation of these com-
pounds (8–12) furnished the corresponding 3-methoxy-, and 3-
benzyloxy-15b-(carboxyl)-alkoxy-estra-1,3,5(10)-trien-17-one deriva-
tives (13–17). The 1,4-addition process of compounds 6 and 7 with
3-hydroxypropionitrile afforded the corresponding 3-methoxy-, and
3-benzyloxy-15b-(2’-cyano)ethoxy-estra-1,3,5(10)-trien-17-ones (18,
19). Cleavage of the 3-benzyloxy group of 19 yielded 20, which
reacted with sulfamoyl chloride to yield 21. Esterification of 15b-
(carboxyl)alkoxy derivatives by diazomethane yielded the corre-
sponding methyl esters 22–24. The 15b-(carboxyl)alkoxy com-
pounds were reacted with oxalyl chloride to give carboxylic acid
chloride which, upon reaction with ammonium hydroxide, morpho-
line or N-cyclohexyl, N-methylamine yielded the corresponding car-
boxamides 25–33. The 3-benzyloxy-15b-(2’-hydroxy)ethoxy- and 3-
benzyloxy-15b-(3’-hydroxy)propoxy-estra-1,3,5(10)-triene-17-ones (10
and 11) reacted with different alkyl- and aryl isocyanates to furnish
alkyl- and aryl urethane derivatives 34–40.
Inhibitory potentials of the C15 estrone derivatives towards
17b-HSD1
Ligand-based approach and the role of reference compounds
Experimental testing and biochemical analysis of the inhibition of
novel compounds provide a feasible way for the development of
inhibitors against 17b-HSD1. This ligand-based approach may also
give valuable information on the molecular basis of substrate
binding and catalytic mechanisms24.
In our present experiments, thirty substituted 15b-alkoxy
estrone derivatives possessing hydroxy, methoxy, benzyloxy and
sulfamate groups in position C3 were investigated. In vitro conver-
sion of estrone (1) to 17b-estradiol (2) was measured and cofac-
tors, either NADPH or NADH were present in excess amounts in
the incubations. Inhibitory effects were evaluated first by relative
conversion measured at 10lM test concentration. For more
potent inhibitors IC50 values were determined. Inhibitory poten-
tials and binding affinities were evaluated in comparison to those
of natural substrate estrone (1) and the parent unsubstituted core
molecules of the inhibitors, including 3-methoxy- and 3-benzy-
loxy-estrone (3 and 4) and estrone-3-sulfamate (5) (EMATE).
Comparative evaluation of inhibitory potentials measured with dif-
ferent cofactors was performed on the basis of RIP parameters
which were calculated in comparison to substrate estrone
(Table 1).
17b-HSD1 inhibition results of the test compounds
Results obtained with NADPH. In the NADPH supplemented incu-
bations compounds 18, 20, and 40 were found to be the most
potent inhibitors (Table 2). Their IC50 values are below 1 mM
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(0.42–0.64 lM), indicating inhibitory effects similar to those of the
unsubstituted parent compounds estrone (1) and 3-methyl-O-
estrone (3) (0.63 and 0.77 lM, respectively). Compounds 11, 21,
22, and 25 proved to be effective inhibitors displaying IC50 close
to 1 mM (0.78–1.5lM). Three compounds of this group (11, 22, 25)
are derivatives of 3-benzyl-O-estrone, and they exert substantially
stronger inhibition in comparison to the unsubstituted core itself.
The IC50 value was found to be 2.7mM for another 3-benzyloxy
compound (9), and that shows a somewhat weaker effect, but still
an improved inhibition when compared to the parent molecule
Scheme 2. Reagents and conditions: (i) and (ii)12,23; (iii) CH2Cl2, hydroxyl alcohol, NaOH; (iv) acetone, Jones reagent; (v) CH2Cl2, hydroxyl alkylnitrile, NaOH; (vi) CH2Cl2,
TEA, hydroxyl alkyl-, or arylisocyanate; (vii) THF, diethylether, CH2N2; (viii) CH2Cl2, oxalyl chloride, amines.
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(4). IC50 values of 23, 24, and 26 were found also in the micromo-
lar range (2.2–5.1mM). These results, however, indicate decreased
potentials compared to the unsubstituted estrone (1) and 3-
methyl-O-estrone (3) cores. Relative conversions measured for the
10mM test concentration of the other compounds in the presence
of NADPH were higher than 50%. These results mean IC50 values
higher than 10mM and reveal a weak inhibitory effect against the
17b-HSD1.
Results obtained with NADH. In experiments performed with
NADH in excess, an outstanding inhibitory potential was measured
for 3-hydroxy compound (35) (IC50 ¼ 0.38mM). Two other 3-
hydroxy compounds (20 and 40) were found to be somewhat less
potent, and their IC50 values (3.2 and 1.4mM, respectively) reflect
similar effects as the unsubstituted estrone. The 3-benzyloxy com-
pound (17) and the 3-sulfamate compound (21) also displayed
medium strengths with IC50 values 3.5mM and 4.0 mM, respect-
ively. The result of 17 indicates an improved inhibition compared
to the basic molecule 3-benzyl-O-estrone (4). Compounds 24, 28,
and 33 displayed moderate inhibitions with IC50 values between
5.6 and 7.0mM. Other compounds exerted weak inhibition when
NADH was applied as cofactor. In these cases, relative conversions
were not suppressed below 50% at the 10mM test concentra-
tion (IC50>10 mM).
Results with NADPH versus NADH. Results measured with NADPH
or NADH showed different tendencies for some of the test com-
pounds when the inhibitory effects of the C15 derivatives were
compared to those of their unsubstituted core compounds. Using
the RIP values, derivative 35 exerted similar effect in the presence
of NADPH than estrone (1) (RIP ¼ 0.66 and 1.0, respectively), but
this compound had a strong 5-fold increase in inhibitory potential,
when NADH was applied (RIP ¼ 0.19). Derivative 18 also dis-
played a maintained effect with NADPH (RIP ¼ 0.89), but showed
diminished potential with NADH (RIP ¼ 10) in comparison to its
unsubstituted core 3-methyl-O-estrone (3). The latter displayed RIP
values 1.2 with NADPH and 2.1 with NADH). C15 substituents
increased the inhibitory potentials in the case of 3-benzyloxy com-
pounds 11, 22, and 25 when NADPH was applied (RIP ¼ 1.2–2.4),
but maintained effects were measured for these derivatives in the
presence of NADH (RIP > 5.0). Compound 17 had an opposite
behavior, that is, it showed improved inhibition with NADH (RIP
¼ 1.8) compared to the unsubstituted core 3-benzyl-O-estrone (4)
((RIP (NADPH) > 15 and RIP (NADH) > 5)). On the other hand, 20
and 40 showed retained potentials with both cofactors compared
to their unsubstituted core estrone (1) with RIP parameters close
to 1 (0.70–1.6). For some other compounds derivatized at C15,
however, decreased inhibitory effects could be observed when
either NADPH or NADH was applied.
Biomedical evaluation of the inhibitory potentials obtained
with NADPH
Literature background. Estrane-based inhibitors, as C15-substi-
tuted derivatives are assumed to occupy the substrate binding
site of 17b-HSD1. Side chains are capable of establishing further
contacts to the enzyme than the substrate molecule itself and, in
this way, they may modulate binding affinity and inhibitory poten-
tial this way5,7,9,25,26. Messinger et al. analysed the X-ray structure
of the 17b-HSD127 and identified a hole in the proximity of the
enzyme’s active site, which is composed of flexible amino acids
Ser222, Leu219 and Met193 as well as Tyr218, Leu96, and
Gly19812. The hole shows its opening towards the environment of
C15 of the steroidal backbone, and thought to be able to accom-
modate side chains with appropriate length, spacer unit, and cap-
ping group. This finding inspired the Messinger group to
synthesize numerous C15-substituted estrone derivatives as pre-
sumed 17b-HSD1 inhibitors and they have identified several
Table 1. Reference parameters of in vitro 17b-HSD1 inhibition of the unsubstituted compounds.
Nr.
Structure 17β-HSD1 inhibition in the presence of 
NADPH
17β-HSD1 inhibition in the presence of 
NADH
IC50 ± SD 
(μM)
Rel. conv. 
(%) at 
10μM ± SD
RIP IC50 ± SD (μM)
Rel. conv. 
(%) at 10μM 
± SD
RIP
1 0.63 ± 0.11 1.0 2.0 ± 0.18 1.0
3
0.77 ± 0.29 1.2 4.2 ± 1.6 2.1
4 >10 52 ± 2 > 15 >10 52 ± 5 > 5
5 0.98 ± 0.71 1.6 2.6 ± 1.6 1.3
IC50: concentration which decreases the enzyme activity to 50%.
Relative conversions (Rel. conv., control incubation with no inhibition is 100%) measured in the presence of 10lM concentration of the compound tested.
Mean ± SD, n¼ 3.
RIP: relative inhibitory potential compared to estrone; SD: standard deviation.
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Table 2. In vitro 17b-HSD1 inhibition of the C15 derivatized test compounds.
Nr. Structure
17β-HSD1 inhibition in the presence 
of NADPH
17β-HSD1 inhibition in the 
presence of NADH
IC50 ± SD 
(μM)
Rel. conv. 
(%) at 
10μM ± SD
RIP IC50 ± SD (μM)
Rel. conv. 
(%) at 
10μM ± 
SD
RIP
11 0.78 ± 0.30 1.2 > 10 76 ± 7 > 5.0
12 2.7 ± 1.6 4.3 > 10 77 ± 5 > 5.0
13 > 10 90 ± 9 > 15 > 10 78 ± 7 > 5.0
14 > 10 88 ± 9 > 15 > 10 76 ± 3 > 5.0
15 > 10 78 ± 6 > 15 10 ± 3 5.1
16 > 10 76 ± 15 > 15 9.7 ± 4.5 4.9
17 > 10 87 ± 4 > 15 3.5 ± 1.0 1.8
18 0.56 ± 0.37 0.89 20 ± 9.0 10
19 > 10 65 ± 4 > 15 > 10 83 ± 1 > 5.0
20 0.64 ± 0.18 1.01 3.2 ± 1.5 1.6
21 1.1 ± 0.14 1.7 4.0±1.5 2.0
22 1.5 ± 0.50 2.4 > 10 60 ± 3 > 5.0
23 5.1 ± 2.3 8.1 > 10 78 ± 2 > 5.0
24 2.2 ± 0.73 3.5 7.0 ± 4.2 3.5
(Continued)
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Table 2. Continued.
25
1.1 ± 0.42 1.7 12 ± 4 6.2
26 4.2±1.8 6.7 11 ± 5 5.5
27 17 ± 6.5 > 15 > 10 65 ± 2 > 5.0
28 > 10 67 ± 4 > 15 5.6 ± 2.2 2.8
29
> 10 58 ± 5 > 15 > 10 71 ± 6 > 5.0
30 12 ± 3 18 13±5.4 6.4
31 > 10 78 ± 9 > 15 > 10 81 ± 8 > 5.0
32 12 ± 4 > 15 13 ± 6 6.7
33 > 10 61 ± 2 > 15 7.0 ± 0.7 3.5
34 21 ± 15 33 > 10 68 ± 6 > 5.0
35 0.42 ± 0.33 0.66 0.38 ± 0.22 0.19
36 > 10 79 ± 5 > 15 > 10 87 ± 3 > 5.0
37 > 10 67 ± 6 > 15 > 10 76 ± 5 > 5.0
38 > 10 80 ± 5 > 15 > 10 79 ± 10 > 5.0
39 > 10 57 ± 1 > 15 > 10 77±3 > 5.0
40 0.45 ± 0.23 0.71 1.4 ± 0.9 0.70
IC50: concentration which decreases the enzyme activity to 50%.
Relative conversions (Rel. conv, control incubation with no inhibition is 100%) measured in the presence of 10 lM concentration of the compound tested.
Mean ± SD, n¼ 3.
RIP: relative inhibitory potential compared to estrone; SD: standard deviation.
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compounds with high potential, displaying IC50 values in the low
nanomolar range12,13.
Further studies also established that 17b-HSD1 accomplished
complex processes in ligand binding sites11,28. That is, the enzyme
protein could change its conformation depending on the inhibitor
molecule offered12. These mechanisms indicate that a very small
change in inhibitor structure can make large differences in the
course of binding to the enzyme12. Inhibitor studies, therefore,
may give ambiguous picture with regard to the binding properties
of the compounds and complete structure–activity relations could
be revealed sometimes scarcely9,11,12.
17b-HSD1 can use either NADPH or NADH as hydride donor for
the estrone (1) to 17b-estradiol (2) transformation. NADPH, in vivo,
seems to be the prevailing cofactor in the process29,30. It is, there-
fore, reasonable to make biomedical evaluation of inhibitor candi-
dates according to their potentials exerted in NADPH
supplemented medium22.
Discussion of test compounds. Among the test compounds, we
investigated four 15b-(2’-cyano)ethoxy derivatives. Three of them,
the 3-methoxy-, 3-hydroxy-, and 3-sulfamate compounds (18, 20,
and 21, respectively) proved to be potent inhibitors. These results
indicate that 15b-(2’-cyano)ethoxy substituent can be a beneficial
side chain concerning 17b-HSD1 inhibitory effect of estrone deriv-
atives possessing different functionalities in their C3 position.
Four 3-benzyloxyestrone derivatives exerted substantial inhibi-
tory effects against 17b-HSD1. Two compounds with 15b-(3’-
hydroxy)propoxy-, and 15b-(4’-hydroxy)butoxy side chain (11 and
12 respectively), as well as the 15b-(1’-methoxycarbonyl)methoxy
derivative 22 and 15b-(2’-carbonylamido)ethoxy derivative 25
were found to be potent inhibitors. Potentials observed for these
compounds are interesting, since very few effective 3-benzyl-O-
estrone derivatives have been published in the literature9,13,21.
Some of the compounds tested display structural similarities to
C15 derivatized estrone-based compounds published earlier as
17b-HSD1 inhibitor candidates12,13 and interesting conclusions can
be arrived at by comparison our inhibitors with their counterparts.
In previous studies 15b-propanolyl and 15b-pentanolyl substitu-
ents were found to be beneficial substituents on estrone concern-
ing 17b-HSD1 inhibition12,13. In our case, the corresponding 15b-
(3’-hydroxy)propoxy- and 15b-(4’hydroxy)butoxy-substituted 3-
benzyl-O-estrone 11 and 12 also displayed considerable inhibi-
tions. We found that the 3-methyl-O-estrone compound bearing a
C15 substituent with a cyclohexyl capping group 33 was a poor
inhibitor. In Messingers’ experiments, however, its non-oxa ana-
logue exerted potent inhibition12,13. A related cyclohexyl deriva-
tive of estrone 35, on the other hand, showed also a strong
inhibitory effect in our tests. The Messinger group found efficient
17b-HSD1 inhibitors of estrone and 3-methyl-O-estrone com-
pounds that bore 15b-substituents containing a morpholino cap-
ping group and long chain with 3–5 methylene units12,13. In
comparison, 15b-oxy-coupled morpholino compounds in our tests
displayed only weak inhibitions. The comparison of oxa-coupled
derivatives with earlier non-oxa analogues indicates the import-
ance of the C15 linker unit in the 17b-HSD1 inhibitory effect of
estrone derivatives. Benchmarking of recent results against earlier
data is not easy, since different studies may be performed with
different methodologies and reference inhibition parameters may
be missing in previous studies. Our best inhibitors, nevertheless,
may be estimated to be equipotent with some of related earlier
C15 derivatives of estrone compounds and non-oxa analogues
studied by Messinger et al12,13.
Our investigations reveal that C15 substituents of the tested
estrogen derivatives have decisive influence in the binding to
17b-HSD1. These results further indicate that remote fragments on
position C3 also determine affinity of the investigated inhibitor
molecules. C15 substituents of the test compounds show high var-
iety in their chemical nature. Compounds found to be potent
inhibitors also possess diverse side chains and it seems difficult to
identify chain length, capping groups or spacer units which can
be definitely beneficial in 17b-HSD1 binding. C15 substituents of
the compounds can be, however, regarded as side chains both
long and flexible. Considering these common features, we may
assume that binding may be promoted by accommodation of
these side chains in the binding hole of 17b-HSD1 that exists in
proximity of C15 positions of ring D as described by
Messinger et al12.
Our experiments identified several potent 17b-HSD1 inhibitors
among 15b-derivatized estrone-based compounds tested. The
results demonstrate definitive influence of C15 substituents as
well as crucial role of different functionalities in position C3.
Structural diversity of the test compounds makes difficult to give
complete structure–activity relationship conclusions, nevertheless,
several interesting observations can be established from the inhib-
ition data set.
Cofactor dependence of the 17b-HSD1 inhibition, a compara-
tive evaluation
Literature background. Both cofactor molecules, NADPH and
NADH, bind to 17b-HSD1 in an extended conformation, with the
nicotinamide moiety pointing towards the active site of the
enzyme. Nicotinamide is relatively flexible in the complex and
the major interactions between cofactor and enzyme occur at the
adenine dinucleotide phosphate part30. Most of these interactions
are common for both NADPH and NADH25,27,31. A major difference
between the two cofactors is, however, that the 20-phosphate
group of NADPH is stabilized mainly through hydrogen bonds
with residues Ser11 and Arg3727,31, whereas the free hydroxyl
groups on adenosine ribose of non-phosphorylated cofactor
NADH may form hydrogen bonds with Ser11, but not with
Arg3731. When a cofactor binds to 17b-HSD1, structural changes
are induced in the area of the substrate binding site as well. An
otherwise disordered loop, which are composed of residues
189–200, may adopt a specific conformation to accommodate
more space for the cofactor in the active centre25,27. Structural dif-
ferences between the holo form and the apo form of the enzyme
may modify interactions of ligands bound in the substrate binding
site. For instance, side chain of a potent inhibitor 3-[3’,17’b-dihy-
droxyestra-1’,3’,5’(10’)-trien-16’b-methyl]-3-benzamide occupies a
different position in the ternary inhibitor complex, which is differ-
ent from that in the binary complex25. Differences in binding of
substrate or inhibitor ligands may also occur when different cofac-
tors are complexed. The NADPH-bound holoenzyme exerts higher
affinity to the substrate estrone than the NADH-bound com-
plex29,30. In an earlier study we observed highly different inhibi-
tory potential and binding affinity of various D-secoestrones
depending on which cofactor (either NADPH or NADH) was
applied in the in vitro experiments22.
Discussion of test compounds, NADPH versus NADH. In our experi-
ments, substantial inhibitory potentials and increased binding
affinities were observed in presence of both cofactors. However,
some of the compounds exerted different inhibitory potentials
towards 17b-HSD1 complexed to NADPH- or NADH-complexed
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 1283
17b-HSD1. Substrate estrone displays different IC50 values depend-
ing on the cofactor applied and RIP parameters reflect more reli-
ably the cofactor-dependent differences in the inhibitor binding.
RIP parameters demonstrate 3–8 fold stronger binding with
NADH than with NADPH for estrone derivatized with a 15b-(1’-
morpholinocarbonyl)methoxy- side chain (28), for 3-methoxy-
estrone and estrone derivatized with 15b-(1’-N-methyl,cyclohexy-
lamino carbonyl)methoxy- and 15b-(2’-cyclohexylcarbamoyloxy)e-
thoxy chains (33 and 35), as well for 3-benzyl-O-estrone
derivative possessing a 15b-(3’-carboxylic)propoxy substituent
(17). Binding of 3-benzyl-O-estrone compounds substituted with
a 15b-(3’-hydroxy)propoxy, 15b-(1’-methoxycarbonyl)methoxy, or
a 15b-(2’-aminocarbonyl)ethoxy side chain (11, 22, and 25) and
3-methyl-O-estrone bearing a 15b-(2’-cyano)methoxy side chain
(18) display similar (2–11 fold) cofactor preference in terms of
RIP values, but these derivatives favour binding to the NADPH
bound enzyme.
Cofactor-dependent affinities of some of the investigated com-
pounds indicate that binding capabilities of the binding hole may
be different depending on the nature of cofactor the enzyme
complexed with. The binding hole suitable to accommodate C15
side chains is known to be formed by amino acids Leu96, Met193,
Gly198, Tyr218, Leu219, and Ser22212. Residues Met193 and
Gly198 are also constituents of the disordered loop (amino acids
189–200) which adopt a specific conformation following cofactor
binding25,27. The presence or absence of 20-phosphate in the
cofactors causes differences in the structure of the holoenzymes.
Furthermore, the area of the substrate binding site may also be
affected in a different way in these complexes25,27,31. We may also
assume that binding of NADPH or NADH modifies the conform-
ation of the loop of residues 189–200 differently. Joint residues
Met193 and Gly198 of the two structural elements transmit this
difference from the loop to the binding hole, and these processes
induce different positioning and binding capabilities of the bind-
ing hole in the holoenzyme variants. Hosting certain C15 side
chains, therefore, might be, therefore, favoured or unfavoured in
the binding hole altered differently upon binding of phosphory-
lated or unphosphorylated cofactors.
In our earlier investigation, potent 17b-HSD1 inhibitory effects
of ring D modified seco-oxime and seco-alcohol estrones were
identified22. In that case we assumed that polar functionalities of
short side chains of compounds studied might establish hydro-
philic interactions or hydrogen bonds towards suitable amino
acids of the enzyme present in close proximity of ring D region.
Binding affinity of certain compounds in that series also displayed
strong cofactor dependence and this phenomenon indicated that
complexation with NADPH or NADH furnished different conforma-
tions to enzyme residues involved in the interactions.
In our present study we identified another group of com-
pounds, C15 derivatized estrones, which may exert cofactor-
dependent inhibition towards the 17b-HSD1. Structural features
and binding mechanisms of side chains in the region of ring D
differ to a great extent for those compounds investigated in our
earlier report and for those presented in this study. Cofactor
dependence of inhibitor binding, however, could be observed in
both series. These results suggest that binding of the phosphory-
lated or the unphosphorylated cofactor may exert different influ-
ence on more areas and structural elements of the substrate
binding site.
Early studies assigned NADH as a catalytic cofactor of 17b-
HSD1 and numerous in vitro inhibition tests have been per-
formed with this recognition. (See corresponding references in
our earlier work22.) Later, however, it became accepted that
NADPH might be the prevalent partner of 17b-HSD1 in its
main in vivo function in the catalysis of the estrone–17b-estra-
diol conversion22,29,30. Our present results obtained with C15
estrone derivatives support that in vitro potentials obtained
with the two cofactors may differ substantially for certain
inhibitor compounds. Data measured in the presence of
NADPH are more relevant in inhibitor optimization and in lead
selection, but NADH results could be valuable in understanding
of the mechanism the inhibition of 17b-HSD1.
Conclusions
17b-HSD1 inhibitory potential of 15b-oxa-coupled estrone deriva-
tives possessing hydroxy, methoxy, benzyloxy and sulfamate func-
tionalities in position C3 has been investigated. Thirty inhibitor
candidates were tested via in vitro radioincubations. We found
several potent 17b-HSD1 inhibitors and the results demonstrated
that potent inhibitory effect could be achieved with both various
C15 substituents, and different C3 functional groups. We identified
four 3- benzyloxyestrone derivatives (11, 22, 25), which exerted
substantial inhibitory effect. We also found that 15b-(2’-cyano)e-
thoxy was a beneficial substituent of compounds bearing different
functionalities in position C3 (18, 19, 20, and 21). A comparison
with earlier non-oxa analogues indicates that beyond the effect of
capping groups and spacer units, there might be a strong influ-
ence of the presence or absence of oxygen in the 15b linker on
the inhibitory potential.
Some of the compounds displayed considerable difference in
binding affinities towards 17b-HSD1 complexed with NADPH or
NADH. It is reasonable to assume that side chains of the potent
compounds can be accommodated in the binding hole of 17b-
HSD1 existing in proximity of the C15 position of ring D of the
steroidal ligands12. This binding hole shares Met193 and Gly198
with a loop element which is known to adopt a specific conform-
ation upon cofactor binding25,27. We suppose that conformation
of this loop may be different in NADPH- or NADH-complexed 17b-
HSD1. Structural differences can be forwarded by the joint amino
acids inducing different positioning and binding capabilities of
the binding hole. Further structural investigations (e.g., molecular
docking studies) may confirm mechanisms involved in binding of
our inhibitor compounds and different binding affinities of the
test compounds exerted towards the holoenzyme variants.
Our investigations provide valuable data on binding processes
of the enzyme and may contribute to the development of new
17b-HSD1 inhibitors, as novel drug molecules acting on
enzyme level.
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